var title_f39_0_39936="CT fluoroscopic guidance";
var content_f39_0_39936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT fluoroscopic guidance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 77-year-old woman with biopsy-proven 1.8 cm left lower lobe adenocarcinoma (stage IA NSCLC) who was not considered a surgical candidate due to chronic obstructive pulmonary disease and cardiac risk factors. Axial CT fluoroscopy image with patient in the prone position shows the RF electrode positioned within the left lower lobe lung cancer. Pleural thickening where local anesthetic was administered (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Schirmang, T, MD and Dupuy, D, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39936=[""].join("\n");
var outline_f39_0_39936=null;
var title_f39_0_39937="Split thickness skin graft and skin mesher";
var content_f39_0_39937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Split thickness skin graft and skin mesher",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A split thickness skin graft is processed through a skin mesher that creates apertures in the graft. This allows for expansion and coverage of a greater wound surface area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge Leon-Villapalos, MD, FRCS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39937=[""].join("\n");
var outline_f39_0_39937=null;
var title_f39_0_39938="Patient information: Muscle strain (The Basics)";
var content_f39_0_39938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/56/4994\">",
"         Patient information: Groin strain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/3/1074\">",
"         Patient information: Hamstring injury (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/25/43409\">",
"         Patient information: Hip pain in older people (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/36/7747\">",
"         Patient information: Knee pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/7/36978\">",
"         Patient information: Low back pain in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/31/23026\">",
"         Patient information: Neck pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/45/17106\">",
"         Patient information: Whiplash (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/46/24289\">",
"         Patient information: Hip pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/4/24642\">",
"         Patient information: Knee pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/47/8950\">",
"         Patient information: Low back pain in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/35/27188\">",
"         Patient information: Neck pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Muscle strain (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/muscle-strain-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H276646807\">",
"      <span class=\"h1\">",
"       What is a muscle strain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A muscle strain can happen when a muscle gets stretched too much or too quickly, or works too hard. This sometimes makes the muscle tear. Another term for a muscle strain is a &ldquo;pulled muscle.&rdquo;",
"     </p>",
"     <p>",
"      A muscle strain can happen during an accident or exercise. Muscles that are commonly strained include those in the back, neck, and back of the leg.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H276646822\">",
"      <span class=\"h1\">",
"       What are the symptoms of a muscle strain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms happen in the area of the muscle strain and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Muscle spasm or tightness",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Bruising",
"       </li>",
"       <li>",
"        Weakness or being unable to move the muscle",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H276646837\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor or nurse should be able to tell if you have a muscle strain by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      Some people need tests. Depending on your symptoms, your doctor or nurse might order an imaging test such as an ultrasound or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H276646852\">",
"      <span class=\"h1\">",
"       How is a muscle strain treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A muscle strain usually gets better on its own, but it can take days to weeks to heal completely.",
"     </p>",
"     <p>",
"      To help your symptoms get better, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest your muscle and avoid movements or activities that cause pain",
"       </li>",
"       <li>",
"        Ice the area &ndash; You can put a cold gel pack, bag of ice, or bag of frozen vegetables on the painful muscle every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin. Use the ice (or other cold object) for at least 6 hours after the injury. Some people find it helpful to ice up to 2 days after an injury.",
"       </li>",
"       <li>",
"        Wrap your muscle with an elastic bandage, other type of wrap, or fabric &ldquo;sleeve&rdquo; (Show Thigh sleeve PI) &ndash; This helps support your muscle.",
"       </li>",
"       <li>",
"        Raise the muscle above the level of your heart (if possible) &ndash; For example, you can prop your leg up on pillows. This is helpful only for the first few days after an injury.",
"       </li>",
"       <li>",
"        Take medicine to reduce the pain and swelling &ndash; If you have a lot of pain or a severe muscle strain, your doctor will prescribe a strong pain medicine. If your strain is not severe, you can take an over-the-counter medicine such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After your pain gets better, your doctor or nurse will recommend that you gently stretch and exercise your muscle. Stretches and exercises can help strengthen your muscles and keep them from getting too stiff.",
"     </p>",
"     <p>",
"      Your doctor or nurse will show you stretches and exercises to do. Or he or she will have you work with a physical therapist (exercise expert).",
"     </p>",
"     <p>",
"      It&rsquo;s important to let your muscle heal before you play sports or do other activities that use the muscle again. If you don&rsquo;t let your muscle heal, you are likely to injure it again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H276646867\">",
"      <span class=\"h1\">",
"       Can a muscle strain be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help prevent a muscle strain by taking time to warm up your muscles before you exercise. You can do this by walking or doing another light activity. If you are not sure how to warm up before exercising, ask your doctor, nurse, or physical therapist.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H276646882\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/31/23026?source=see_link\">",
"       Patient information: Neck pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/45/17106?source=see_link\">",
"       Patient information: Whiplash (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/7/36978?source=see_link\">",
"       Patient information: Low back pain in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/36/7747?source=see_link\">",
"       Patient information: Knee pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/25/43409?source=see_link\">",
"       Patient information: Hip pain in older people (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/56/4994?source=see_link\">",
"       Patient information: Groin strain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1074?source=see_link\">",
"       Patient information: Hamstring injury (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24642?source=see_link\">",
"       Patient information: Knee pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/46/24289?source=see_link\">",
"       Patient information: Hip pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=see_link\">",
"       Patient information: Low back pain in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/35/27188?source=see_link\">",
"       Patient information: Neck pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/0/39938?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83535 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39938=[""].join("\n");
var outline_f39_0_39938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276646807\">",
"      What is a muscle strain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276646822\">",
"      What are the symptoms of a muscle strain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276646837\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276646852\">",
"      How is a muscle strain treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276646867\">",
"      Can a muscle strain be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276646882\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/56/4994?source=related_link\">",
"      Patient information: Groin strain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1074?source=related_link\">",
"      Patient information: Hamstring injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/46/24289?source=related_link\">",
"      Patient information: Hip pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/25/43409?source=related_link\">",
"      Patient information: Hip pain in older people (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/36/7747?source=related_link\">",
"      Patient information: Knee pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/35/27188?source=related_link\">",
"      Patient information: Neck pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/31/23026?source=related_link\">",
"      Patient information: Neck pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/45/17106?source=related_link\">",
"      Patient information: Whiplash (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_0_39939="Heller myotomy with Toupet fundoplication";
var content_f39_0_39939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heller myotomy with Toupet fundoplication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission. Copyright &copy; University of Washington.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39939=[""].join("\n");
var outline_f39_0_39939=null;
var title_f39_0_39940="Rimexolone: Patient drug information";
var content_f39_0_39940=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rimexolone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/13/20691?source=see_link\">",
"     see \"Rimexolone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vexol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vexol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rimexolone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705252",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a very bad eye infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11185 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39940=[""].join("\n");
var outline_f39_0_39940=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217247\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016112\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016111\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016116\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016117\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016119\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016114\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016115\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016120\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016121\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/13/20691?source=related_link\">",
"      Rimexolone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_0_39941="Scopolamine (systemic): Pediatric drug information";
var content_f39_0_39941=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Scopolamine (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32375?source=see_link\">",
"    see \"Scopolamine (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/12/10437?source=see_link\">",
"    see \"Scopolamine (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9522574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Transderm Scp&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9522575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Buscopan&reg;;",
"     </li>",
"     <li>",
"      Scopolamine Hydrobromide Injection;",
"     </li>",
"     <li>",
"      Transderm-V&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10514529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent, Transdermal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10514633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32375?source=see_link\">",
"      see \"Scopolamine (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Preoperatively and antiemetic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 6 mcg/kg/dose (maximum dose: 0.3 mg/dose); may be repeated every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 0.3-0.65 mg; may be repeated 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transdermal: Adults: Apply 1 disc behind the ear the evening before surgery; if prior to cesarean section, apply 1 hour prior to minimize exposure to infant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Motion sickness:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Children &gt;12 years and Adults: 1-2 tablets 1 hour prior to exposure; may repeat after 8 hours of continued exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transdermal: Children &gt;12 years and Adults: Apply 1 disc behind the ear at least 4 hours prior to exposure every 3 days as needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9522694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrobromide: 0.4 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transderm Scp&reg;: 1.5 mg (4s, 10s, 24s) [contains metal; releases ~1 mg over 72 hours]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9522579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10514634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered without regard to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V.: Dilute with an equal volume of SWI and administer by direct I.V. injection over 2-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal: Transdermal patch is programmed to deliver 1 mg over 3 days. Once applied, do not remove the patch for 3 full days. Apply patch to hairless area behind one ear; wash hands before and after application; if becomes dislodged, replace with fresh patch",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9522627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Butylbromide injection: Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, Ringer's solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydrobromide injection: Avoid acid solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Hydrobromide: Compatible:",
"     </b>",
"     Fentanyl, heparin, hydrocortisone sodium succinate, hydromorphone, methadone, morphine, potassium chloride, propofol, sufentanil, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hydrobromide: Compatible:",
"     </b>",
"     Atropine, butorphanol, chlorpromazine, cimetidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydromorphone, hydroxyzine, meperidine, methotrimeprazine, metoclopramide, midazolam, morphine, nalbuphine, pentazocine, pentobarbital, prochlorperazine edisylate, promethazine, ranitidine, sufentanil, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Butylbromide: Compatible:",
"     </b>",
"     Dimenhydrinate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Haloperidol.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10514590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection and tablet: Store at room temperature 15&deg;C to 30&deg;C (58&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal system: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Physically compatible when mixed in the same syringe with atropine, butorphanol, chlorpromazine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydromorphone, hydroxyzine, meperidine, metoclopramide, morphine, pentazocine, pentobarbital, perphenazine, prochlorperazine, promazine, promethazine, or thiopental",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10514539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preoperative medication to produce amnesia and decrease salivary and respiratory secretions; prevention of motion sickness (oral and transdermal formulations) and prevention of postoperative nausea and vomiting (transdermal formulation); inhibits excessive motility and hypertonus of the GI tract in such conditions as the irritable colon syndrome, mild dysentery, diverticulitis, and pylorospasm (oral formulation)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9522566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9522600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, flushing, orthostatic hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Acute toxic psychosis (rare), agitation (rare), ataxia, confusion, delusion (rare), disorientation, dizziness, drowsiness, fatigue, hallucination (rare), headache, irritability, loss of memory, paranoid behavior (rare), restlessness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Drug eruptions, dry skin, dyshidrosis, erythema, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, dry throat, dysphagia, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Accommodation impaired, blurred vision, conjunctival infection, cycloplegia, dryness, glaucoma (narrow-angle), increased intraocular pain, itching, photophobia, pupil dilation, retinal pigmentation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dry nose, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (rare), anaphylactic shock (rare), angioedema, diaphoresis decreased, heat intolerance, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10514540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to scopolamine or any component; patients hypersensitive to belladonna or barbiturates may be hypersensitive to scopolamine; GI or GU obstruction, thyrotoxicosis, tachycardia secondary to cardiac insufficiency, paralytic ileus, myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10514583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution with hepatic or renal dysfunction since adverse CNS effects occur more often in these patients; use with caution in infants and children since they may be more susceptible to adverse effects of scopolamine; use with caution in patients with cardiac disease, seizures, or psychoses",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10514541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug withdrawal symptoms such as nausea, vomiting, headache, dizziness, and equilibrium disturbance have been reported following removal of transdermal system, primarily in patients using the system for more than 3 days; discontinue if patient reports unusual visual disturbances or pain within the eye. Patients with idiosyncratic reactions to anticholinergics, including scopolamine, may experience disorientation, delirium, and/or marked somnolence; may be accompanied by dilated pupils, rapid pulse, and xerostomia. Safety and efficacy have not been established for use of transdermal and oral scopolamine in children.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI. Scopolamine (hyoscine) hydrobromide should not be interchanged with scopolamine butylbromide formulations; dosages are not equivalent.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9522602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9522581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9522582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; embryotoxic events were observed in some studies. Scopolamine crosses the placenta; may cause respiratory depression and/or neonatal hemorrhage when used during pregnancy. Transdermal scopolamine has been used as an adjunct to epidural anesthesia for cesarean delivery without adverse CNS effects on the newborn. Parenteral administration does not increase the duration of labor or affect uterine contractions. Except when used prior to cesarean section, use during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10514592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands and the CNS, resulting in anticholinergic activity (inhibition of secretion of saliva and sweat, decreased GI motility and secretions, increased heart rate, drowsiness, depressed motor function); antagonizes histamine and serotonin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10514601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral, I.M.: 30 minutes to 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transdermal: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral, I.M.: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transdermal: 72 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10514602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well absorbed by all routes of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 9.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: &lt;5% excreted unchanged in the urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10514635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/12/10437?source=see_link\">",
"      see \"Scopolamine (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; avoid alcohol; wash hands thoroughly with soap and water after handling the patch as dilation of pupils and blurred vision may occur if contact with eye; dispose of patches properly to avoid contact with children or pets; remove patch immediately if experiencing difficulty urinating or pain and reddening of eyes accompanied by dilated pupils",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16045 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39941=[""].join("\n");
var outline_f39_0_39941=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522574\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522575\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514529\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514633\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522694\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522579\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514634\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522627\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514590\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514539\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522566\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522600\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514540\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514583\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514541\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300031\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522602\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522581\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522582\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514592\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514601\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514602\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514635\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16045|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/58/24484?source=related_link\">",
"      Scopolamine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/8/4228?source=related_link\">",
"      Scopolamine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/56/9092?source=related_link\">",
"      Scopolamine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32375?source=related_link\">",
"      Scopolamine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/12/10437?source=related_link\">",
"      Scopolamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_0_39942="Antihemophilic factor/von Willebrand factor complex (human): Drug information";
var content_f39_0_39942=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antihemophilic factor/von Willebrand factor complex (human): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/51/23348?source=see_link\">",
"    see \"Antihemophilic factor/von Willebrand factor complex (human): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/22/9575?source=see_link\">",
"    see \"Antihemophilic factor/von Willebrand factor complex (human): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3000299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alphanate&reg; ;",
"     </li>",
"     <li>",
"      Humate-P&reg;;",
"     </li>",
"     <li>",
"      Wilate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humate-P&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3000342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antihemophilic Agent;",
"     </li>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3000410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Factor VIII deficiency: General guidelines (consult specific product labeling for Alphanate&reg; or Humate-P&reg;):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment; in general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor hemorrhage: Loading dose: FVIII:C 15 units/kg to achieve FVIII:C plasma level ~30% of normal. If second infusion is needed, half the loading dose may be given once or twice daily for 1-2 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hemorrhage: Loading dose: FVIII:C 25 units/kg to achieve FVIII:C plasma level ~50% of normal; Maintenance: FVIII:C 15 units/kg every 8-12 hours for 1-2 days in order to maintain FVIII:C plasma levels at 30% of normal. Repeat the same dose once or twice daily for up to 7 days or until adequate wound healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Life-threatening hemorrhage/major surgery: Loading dose: FVIII:C 40-50 units/kg; Maintenance: FVIII:C 20-25 units/kg every 8-12 hours to maintain FVIII:C plasma levels at 80% to 100% of normal for 7 days. Continue same dose once or twice daily for another 7 days in order to maintain FVIII:C levels at 30% to 50% of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      von Willebrand disease (VWD): Treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Humate-P&reg;:",
"      </i>",
"     </b>",
"     I.V.: Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment; in general, administration of factor VIII 1 unit/kg would be expected to raise circulating VWF:RCo ~5 units/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Type 1, mild VWD: Minor hemorrhage (if desmopressin is not appropriate) or major hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: VWF:RCo 40-60 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: VWF:RCo 40-50 units/kg every 8-12 hours for 3 days, keeping VWF:RCo nadir &gt;50%; follow with 40-50 units/kg daily for up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Type 1, moderate or severe VWD:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Minor hemorrhage: VWF:RCo 40-50 units/kg for 1-2 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Major hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Loading dose: VWF:RCo 50-75 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance dose: VWF:RCo 40-60 units/kg every 8-12 hours for 3 days to keep the VWF:RCo nadir &gt;50%, then 40-60 units/kg daily for a total of up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Types 2 and 3 VWD:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Minor hemorrhage: VWF:RCo 40-50 units/kg for 1-2 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Major hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Loading dose: VWF:RCo 60-80 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance dose: VWF:RCo 40-60 units/kg every 8-12 hours for 3 days, keeping the VWF:RCo  nadir &gt;50%; follow with 40-60 units/kg daily for a total of up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Wilate&reg;:",
"      </i>",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: VWF:RCo: 20-40 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 20-30 units/kg every 12-24 hours for &le;3 days, keeping the VWF:RCo nadir &gt;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: VWF:RCo: 40-60 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 20-40 units/kg every 12-24 hours for 5-7 days, keeping the VWF:RCo nadir &gt;50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      von Willebrand disease (VWD): Prophylaxis:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Alphanate&reg;:",
"      </i>",
"     </b>",
"     <i>",
"      Surgery/procedure prophylaxis (except patients with type 3 undergoing major surgery):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Preoperative dose:",
"     </i>",
"     VWF:RCo: 60 units/kg 1 hour prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     VWF:RCo: 40-60 units/kg every 8-12 hours as clinically needed. May reduce dose after third postoperative day; continue treatment until healing is complete. For minor procedures, maintain VWF of 40% to 50% during postoperative days 1-3; for major procedures maintain VWF of 40% to 50% for &ge;3-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Humate-P&reg;:",
"      </i>",
"     </b>",
"     <i>",
"      Surgery/procedure prevention of bleeding:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Emergency surgery:",
"     </i>",
"     Administer VWF:RCo 50-60 units/kg; monitor trough coagulation factor levels for subsequent doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Surgical management (nonemergency):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose calculation based on baseline target VWF:RCo: (Target peak VWF:RCo - Baseline VWF:RCo) x weight (in kg) / IVR = units VWF:RCo required. Administer loading dose 1-2 hours prior to surgery.",
"     <b>",
"      Note:",
"     </b>",
"     If",
"     <i>",
"      in vivo",
"     </i>",
"     recovery (IVR) not available, assume 2 units/dL per units/kg of VWF:RCo product administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Target concentrations for VWF:RCo following loading dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Major surgery: 100 units/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Minor surgery: 50-60 units/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: Initial: One-half loading dose, followed by subsequent dosing determined by target trough concentrations, generally every 8-12 hours. Patients with shorter half-lives may require dosing every 6 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Target maintenance trough VWF:RCo concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Major surgery: &gt;50 units/dL for up to 3 days, followed by &gt;30 units/dL for a minimum total treatment of 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Minor surgery: &ge;30 units/dL for a minimum duration of 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral surgery: &ge;30 units/dL for a minimum duration of 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3000409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/22/9575?source=see_link\">",
"      see \"Antihemophilic factor/von Willebrand factor complex (human): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Factor VIII deficiency:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      von Willebrand disease (VWD): Treatment:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      von Willebrand disease (VWD): Prophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Surgery/procedure prophylaxis (except patients with type 3 undergoing major surgery) (Alphanate&reg;):",
"     </i>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Preoperative dose:",
"     </i>",
"     VWF:RCo: 75 units/kg 1 hour prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     VWF:RCo: 50-75 units/kg every 8-12 hours as clinically needed. May reduce dose after third postoperative day; continue treatment until healing is complete.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Surgery/procedure prevention of bleeding (Humate-P&reg;):",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3000411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3000423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alphanate&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250 units [Factor VIII and VWF:RCo ratio varies by lot; contains sodium &ge;10 mEq/vial, albumin and polysorbate 80; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500 units [Factor VIII and VWF:RCo ratio varies by lot; contains sodium &ge;10 mEq/vial, albumin and polysorbate 80; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1000 units [Factor VIII and VWF:RCo ratio varies by lot; contains sodium &ge;10 mEq/vial, albumin and polysorbate 80; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1500 units [Factor VIII and VWF:RCo ratio varies by lot; contains sodium &ge;10 mEq/vial, albumin and polysorbate 80; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humate-P&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 250 units and VWF:RCo 600 units [contains albumin; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 500 units and VWF:RCo 1200 units [contains albumin; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 1000 units and VWF:RCo 2400 units [contains albumin; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wilate&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 450 units and VWF:RCo 450 units [contains polysorbate 80 (in diluent); packaged with diluent] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 500 units and VWF:RCo 500 units [contains polysorbate 80 (in diluent); packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 900 units and VWF:RCo 900 units [contains polysorbate 80 (in diluent); packaged with diluent] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 1000 units and VWF:RCo 1000 units [contains polysorbate 80 (in diluent); packaged with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3000444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3000417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alphanate&reg;: Infuse slowly (maximum rate: 10 mL/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Humate-P&reg;: Infuse slowly (maximum rate: 4 mL/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wilate&reg;: Infuse slowly at a rate of 2-4 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3000345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Factor VIII deficiency: Alphanate&reg;, Humate-P&reg;: Prevention and treatment of hemorrhagic episodes in patients with hemophilia A (classical hemophilia) or acquired factor VIII deficiency (Alphanate&reg; only);",
"     <b>",
"      Note:",
"     </b>",
"     Wilate&reg; is not approved for use in patients with hemophilia A or acquired factor VIII deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     von Willebrand disease (VWD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alphanate&reg;: Prophylaxis with surgical and/or invasive procedures in patients with VWD when desmopressin is either ineffective or contraindicated;",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for patients with severe VWD undergoing major surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humate-P&reg;: Treatment of spontaneous or trauma-induced bleeding, as well as prevention of excessive bleeding during and after surgery in patients with severe VWD, including mild or moderate disease where use of desmopressin is known or suspected to be inadequate;",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for the prophylaxis of spontaneous bleeding episodes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wilate&reg;: Treatment of spontaneous and trauma-induced bleeding in patients with severe VWD, including mild or moderate disease where use of desmopressin is known or suspected to be inadequate or contraindicated;",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for prophylaxis of spontaneous bleeding or prevention of excessive bleeding during and after surgery)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11595830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor VIII may be confused with Factor XIII",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3000355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiorespiratory arrest, chest tightness, edema, femoral venous thrombosis, flushing, hypervolemia, orthostatic hypotension, shock, thromboembolic events, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, headache, lethargy, pain, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Parotid gland swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hematocrit decreased (moderate), hemorrhage, hemolysis, pseudothrombocytopenia (severe)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site stinging, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Extremity pain, joint pain, paresthesia, rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pharyngitis, pulmonary embolus (large doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactic reactions, factor VIII inhibitor formation, hypersensitivity reactions, von Willebrand factor inhibitor formation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3000350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor formulations; hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3000351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibody formation: Neutralizing antibodies (inhibitors) may develop to factor VIII or von Willebrand factor, particularly in patients with type 3 (severe) von Willebrand disease. Patients who develop antibodies against von Willebrand factor will not have an effective clinical response to therapy and infusions may result in anaphylactic reactions; these patients should be managed by an experienced physician and alternatives to therapy should be considered. Any patient who has an inadequate response to therapy or a severe adverse reaction should be evaluated for the presence of inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Allergic reactions, including anaphylaxis, have been observed; monitor patients closely during infusion; patients experiencing anaphylactic reactions should be evaluated for the presence of inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Risk of thromboembolic events may be increased with ongoing use; monitor concentrations of von Willebrand factor and factor VIII closely; use with caution when treating VWD patients with risk factors for thrombosis; avoid excessive increases in factor VIII activity. Incidence of thrombosis may be increased in females.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood types A, B, and AB: Alphanate&reg;, Humate-P&reg; contain trace amounts of blood groups A and B isohemagglutinins. Use caution when large or frequently repeated doses are given to individuals with blood groups A, B, and AB; the patient should be monitored for signs of progressive anemia and the possibility of intravascular hemolysis should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Strongly consider hepatitis A and B vaccination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Some products may contain polysorbate 80.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3000346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3000347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Safety and efficacy in pregnant women have not been established. Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3000349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9406194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Alphanate/VWF Complex/Human Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 unit (1): $1.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $1.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $1.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 unit (1): $1.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Humate-P Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-600 unit (1): $1.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-1200 unit (1): $1.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000-2400 unit (1): $1.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Wilate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-500 unit (1): $1.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000-1000 unit (1): $1.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3000419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Heart rate and blood pressure (before and during I.V. administration); AHF levels prior to and during treatment; in patients with circulating inhibitors, the inhibitor level should be monitored; hematocrit; monitor for signs and symptoms of intravascular hemolysis; bleeding; VWF activity (circulating levels of functional VWF are measured as ristocetin cofactor activity [VWF:RCo]). In surgical patients, monitor VWF:RCo at baseline and after surgery, trough VWF:RCo and FVIII:C at least daily.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3000416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII:C",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe: Factor level &lt;1% of normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate: Factor level 1% to 5% of normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild: Factor level &gt;5% to 30% of normal",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3000361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Factor VIII and von Willebrand factor (VWF), obtained from pooled human plasma, are used to replace endogenous factor VIII and VWF in patients with hemophilia or VWD. Factor VIII in conjunction with activated factor IX, activates factor X which converts prothrombin to thrombin and fibrinogen to fibrin. VWF promotes platelet aggregation and adhesion to damaged vascular endothelium and acts as a stabilizing carrier protein for factor VIII. (Circulating levels of functional VWF are measured as ristocetin cofactor activity [VWF:RCo].)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3000404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: Shortening of bleeding time: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: VWD: Shortening of bleeding time: &lt;6 hours postinfusion; presence of VWF multimers detected in the plasma: &ge;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : VWF:RCo: 53-72 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Factor VIII coagulant activity (FVIII:C): Range: 8-28 hours in patients with hemophilia A",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VWF:RCo: Range: 3-34 hours in patients with VWD",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berntorp E, &ldquo;Plasma Product Treatment in Various Types of von Willebrand Disease,&rdquo;",
"      <i>",
"       Haemostasis",
"      </i>",
"      , 1994, 24(5):289-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/0/39942/abstract-text/7843640/pubmed\" id=\"7843640\" target=\"_blank\">",
"        7843640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berntorp E and Windyga J, &ldquo;Treatment and Prevention of Acute Bleeding in von Willebrand Disease -- Efficacy and Safety of Wilate&reg;, A New Generation von Willebrand Factor/Factor VIII Concentrate,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2009, 15(1):122-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/0/39942/abstract-text/19149848/pubmed\" id=\"19149848\" target=\"_blank\">",
"        19149848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Federici AB, &ldquo;Clinical Diagnosis of von Willebrand's Disease,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2004, 10(Suppl 4):169-76.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kreuz W, Mentzer D, Becker S, et al, &ldquo;Haemate P in Children With von Willebrand's Disease,&rdquo;",
"      <i>",
"       Haemostasis",
"      </i>",
"      , 1994, 24(5):304-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/0/39942/abstract-text/7843642/pubmed\" id=\"7843642\" target=\"_blank\">",
"        7843642",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peterson CW, &ldquo;Treating Hemophilia,&rdquo;",
"      <i>",
"       Am Pharm",
"      </i>",
"      , 1994, NS34(8):57-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scharrer I, Vigh T, and Aygoren-Purun E, &ldquo;Experience With Haemate P in von Willebrand's Disease in Adults,&rdquo;",
"      <i>",
"       Haemostasis",
"      </i>",
"      , 1994, 24(5):298-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/0/39942/abstract-text/7843641/pubmed\" id=\"7843641\" target=\"_blank\">",
"        7843641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White GC, Rosendaal F, Aledort LM, et al, &ldquo;Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2001, 85(3):560.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/0/39942/abstract-text/11307831/pubmed\" id=\"11307831\" target=\"_blank\">",
"        11307831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8782 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39942=[""].join("\n");
var outline_f39_0_39942=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000299\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663155\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000342\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000410\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000409\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000411\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673191\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673192\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000423\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000444\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000417\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000345\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595830\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000355\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000350\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000351\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298759\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218025\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000346\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000347\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000349\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9406194\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322944\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000419\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000416\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000361\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000404\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8782\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8782|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/51/23348?source=related_link\">",
"      Antihemophilic factor/von Willebrand factor complex (human): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/22/9575?source=related_link\">",
"      Antihemophilic factor/von Willebrand factor complex (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_0_39943="Atypical nevus";
var content_f39_0_39943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61488%7EONC%2F68734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61488%7EONC%2F68734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinically atypical nevus with irregular borders and irregular pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical melanocytic nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple melanocytic nevi on the posterior trunk, some of which are large in size (&gt;6 mm)and/or have variegated pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clara Curiel-Lewandrowski, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39943=[""].join("\n");
var outline_f39_0_39943=null;
var title_f39_0_39944="Aspirin exacerbated respiratory disease";
var content_f39_0_39944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aspirin exacerbated respiratory disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39944/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39944/contributors\">",
"     Elliot Israel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39944/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39944/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39944/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39944/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39944/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39944/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/0/39944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    exacerbated respiratory disease (AERD) refers to the combination of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Chronic rhinosinusitis (CRS) with nasal polyposis",
"     </li>",
"     <li>",
"      Reactions to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (acetylsalicylic acid, ASA) and other COX-1 inhibiting nonsteroidal antiinflammatory drugs (NSAIDs), in which symptoms typically begin 30 minutes to 3 hours after ingestion and typically involve bronchospasm and nasal congestion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with AERD are also described as having",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -sensitive asthma or aspirin intolerance, although these terms refer to just one component of the disorder. The term AERD places emphasis on the upper and lower respiratory disease as the fundamental disorder and NSAIDs as an exacerbating factor rather than the underlying cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In keeping with this, avoidance of NSAIDs by these patients does not result in resolution of asthma or CRS.",
"   </p>",
"   <p>",
"    The first case of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitivity in a patient with asthma was described in 1902, a few years after the introduction of aspirin into clinical use. In 1968, Samter and Beers described a triad consisting of asthma, aspirin sensitivity, and nasal polyps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/3\">",
"     3",
"    </a>",
"    ], which came to be known as Samter's triad.",
"   </p>",
"   <p>",
"    In this topic review, the term NSAID includes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (ASA). However, in some parts of this topic, aspirin is discussed exclusive of other NSAIDs.",
"   </p>",
"   <p>",
"    An overview of AERD, with emphasis on pathophysiology and the management of asthma, will be presented in this topic review. Other types of hypersensitivity reactions to NSAIDS and the treatment of patients with chronic rhinosinusitis and nasal polyposis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PSEUDOALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions to NSAIDs in patients with AERD are classified as \"pseudoallergic\" because they are not IgE-mediated. Unlike IgE-mediated reactions, which result from the formation of antibodies against a specific drug, haptenated drug, or a group of structurally similar drugs, pseudoallergic reactions are triggered by a wide range of structurally distinct medications that have in common the ability to inhibit the COX-1 enzyme. Thus, these reactions represent an abnormal biochemical response to the pharmacologic actions of NSAIDs.",
"   </p>",
"   <p>",
"    There are several different types of pseudoallergic reactions to NSAIDs. AERD is categorized as type 1. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=see_link&amp;anchor=H4#H4\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Pseudoallergic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AERD typically have chronic asthma and rhinosinusitis that are acutely exacerbated by the ingestion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other NSAIDs. Reactions typically begin 30 minutes to 3 hours after NSAID ingestion, and may be slow to resolve (",
"    <a class=\"graphic graphic_figure graphicRef65038 \" href=\"mobipreview.htm?28/17/28957\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The classic reaction following NSAID ingestion consists of one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthmatic symptoms, including wheezing, cough, and chest tightness",
"     </li>",
"     <li>",
"      Nasal and ocular symptoms, including nasal",
"      <span class=\"nowrap\">",
"       congestion/obstruction,",
"      </span>",
"      rhinorrhea, periorbital edema,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      injection of the conjunctiva",
"     </li>",
"     <li>",
"      Facial",
"      <span class=\"nowrap\">",
"       flushing/erythema",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During these respiratory reactions, hives may occur in approximately 15 percent of patients. However, isolated hives and angioedema (without respiratory symptoms) are more characteristic of a distinct syndrome characterized by COX-1 sensitivity without asthma, called NSAID-induced",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=see_link&amp;anchor=H4#H4\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Pseudoallergic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional symptoms may occur in patients with severe respiratory reactions. These include angioedema, laryngospasm, abdominal cramps, epigastric pain, and hypotension. Severe reactions may be difficult to distinguish from anaphylaxis.",
"   </p>",
"   <p>",
"    The symptoms are dose-related, ie, small doses of NSAIDs may produce minimal symptoms (such as isolated nasal congestion), whereas larger doses may induce severe bronchospasm requiring intubation. Fatal reactions have rarely occurred following full NSAIDs doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    exacerbated respiratory disease (AERD) is usually diagnosed in adulthood, although children and adolescents may be affected. The three component disorders of AERD develop serially over a period of years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The majority of patients initially develop refractory rhinitis, which is usually established by early thirties. This is followed by the development of chronic hypertrophic eosinophilic rhinosinusitis, characterized by anosmia and nasal polyposis. Symptoms related to nasal polyposis and chronic rhinosinusitis may be more troubling to the patient on a day-to-day basis than recurrent asthma symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/1\">",
"     1",
"    </a>",
"    ], and some undergo repeated sinus surgeries and polypectomies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As the rhinosinusitis worsens, the patient typically develops inflammation in the lower airway and is diagnosed with asthma. At some point during this progression,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"      aspirin",
"     </a>",
"     /NSAID",
"    </span>",
"    sensitivity appears. The asthma and chronic sinusitis of AERD usually become more severe over time, even with NSAID avoidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/2,6-8\">",
"     2,6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In rare cases, the NSAID sensitivity develops first, and NSAID intolerance is an independent risk factor for developing asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of NSAID sensitivity among the general asthmatic population is probably less than 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/7\">",
"     7",
"    </a>",
"    ], although studies of variable rigor have reported higher rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ]. Among glucocorticoid-dependent asthmatics and asthmatics with chronic rhinosinusitis and nasal polyps, NSAID sensitivity may affect up to 20 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of AERD is not fully understood. There appears to be overproduction of proinflammatory arachidonic acid products, particularly the leukotrienes. Overproduction of leukotrienes may result from decreased inhibition of the 5-lipoxygenase pathway of arachidonic acid metabolism by the prostaglandin PGE2, which is further exacerbated by the action of COX1 inhibitors (which block production of PGE2). In addition, there may be decreased elaboration of downregulatory fatty acid products such as lipoxins. Collectively, these abnormalities result in an imbalance between proinflammatory and antiinflammatory mediators. Arachidonic acid metabolism, the role of mast cells, and other identified abnormalities in patients with AERD are reviewed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arachidonic acid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arachidonic acid (AA) is derived from the membrane phospholipids of many cell types, and is metabolized along different pathways to yield various lipid mediators. Some of these mediators are proinflammatory, some are antiinflammatory, and a few can act in both capacities, depending upon the target cell. A simplified overview of arachidonic acid metabolism is provided here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     5-lipoxygenase pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of AA by the enzyme 5-lipoxygenase (5-LO) generates the leukotrienes (LTs), as depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef50924 \" href=\"mobipreview.htm?24/11/24765\">",
"     figure 2",
"    </a>",
"    ). The cysteinyl leukotrienes (cysLTs), LTC4, LTD4, and LTE4, are potent inducers of bronchoconstriction, mucus secretion, nasal mucosal swelling, and airway edema, and attract eosinophils into the airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. These are the major leukotrienes synthesized by eosinophils and mast cells, cell types that are abundant in inflamed airways.",
"   </p>",
"   <p>",
"    Leukotriene B4 (a non-cysLT) is also proinflammatory, but with effects on neutrophils and monocytes. Yet another 5-lipoxygenase product, 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE), is a very potent eosinophil chemoattractant (",
"    <a class=\"graphic graphic_figure graphicRef50924 \" href=\"mobipreview.htm?24/11/24765\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cyclooxygenase pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of AA by cyclooxygenase (COX) enzymes (also called prostaglandin synthases) yields prostaglandins and thromboxanes (",
"    <a class=\"graphic graphic_figure graphicRef76922 \" href=\"mobipreview.htm?16/12/16590\">",
"     figure 3",
"    </a>",
"    ). One of the prostaglandins, PGD2, is predominantly produced by mast cells and has a bronchoconstrictor effect; it appears to be overproduced at baseline in AERD and further increased after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast, PGE2 is a bronchodilator with potent antiinflammatory effects. PGE2 is believed to act as a \"brake\" on the production of the proinflammatory leukotrienes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abnormalities in AERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;AERD patients demonstrate increased concentrations of the proinflammatory products and underproduction of the antiinflammatory products of the 5-lipoxygenase pathway compared to non-AERD asthmatics, both at baseline and following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. The following abnormalities have been identified in patients with AERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/20-31\">",
"     20-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary cellular source of leukotriene LTC4 in patients with AERD appears to be the bronchial mast cell, although eosinophils are also capable of producing large amounts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/22\">",
"       22",
"      </a>",
"      ]. Both cell types are increased and activated in the respiratory tracts of patients with AERD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The enzyme that mediates the formation of LTC4, LTC4 synthase, is overexpressed by eosinophils and other leukocytes in both nasal and pulmonary tissues of some patients with AERD (",
"      <a class=\"graphic graphic_figure graphicRef50924 \" href=\"mobipreview.htm?24/11/24765\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/23,26\">",
"       23,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal levels of platelets aggregated with leukocytes (specifically, neutrophils, eosinophils, and monocytes) were demonstrated in nasal polyp tissue and peripheral blood from patients with AERD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/32\">",
"       32",
"      </a>",
"      ]. When closely associated, platelets and leukocytes can share metabolic processes (ie, transcellular synthesis) to produce enhanced amounts of proinflammatory leukotrienes. In patients with AERD, the percentages of platelet&ndash;leukocyte aggregates correlated with markers of systemic cysteinyl leukotriene production, suggesting that these aggregates may play a role in the enhanced production of leukotrienes.",
"     </li>",
"     <li>",
"      Leukocytes in the nasal mucosa of patients with AERD over express receptors for leukotrienes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medications that inhibit leukotriene synthesis or antagonize leukotriene receptors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"       zileuton",
"      </a>",
"      , etc) blunt or block the bronchoconstrictive response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/13,33-35\">",
"       13,33-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levels of PGE2 in polyp tissue and lower airway fibroblasts of AERD patients are reduced at baseline and fall further after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      challenge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. PGE2 is believed to act as a brake on leukotriene production, as mentioned previously. The inhalation of PGE2 has been shown to prevent the reaction to inhaled forms of acetylsalicylic acid (ie, lysyl-aspirin), as well as the rise in cysLTs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/39\">",
"       39",
"      </a>",
"      ] suggesting that altered PGE2 homeostasis may be key to this disorder. Additionally, several isoforms of the PGE receptors are reduced on the inflammatory cells in nasal polyp and bronchial tissues of AERD patients, further suggesting that altered PGE homeostasis may contribute to AERD. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levels of lipoxin A1, an antiinflammatory product of the 5-LO pathway, are reduced in AERD patients (",
"      <a class=\"graphic graphic_figure graphicRef50924 \" href=\"mobipreview.htm?24/11/24765\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, these findings suggest that there is a baseline dysregulation of arachidonic acid metabolism in patients with AERD, leading to overproduction and possibly oversensitivity of certain cells or tissues to proinflammatory leukotrienes, and resulting in persistent airway inflammation. This dysregulation is acutely exaggerated by COX-1 inhibition, perhaps because the synthesis of PGE2 is reduced and the \"brake\" on leukotrienes is released [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/39,40,42,43\">",
"     39,40,42,43",
"    </a>",
"    ]. Additionally, platelets may play a role in this process by providing machinery to produce leukotrienes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Involvement of mast cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells may represent an important source of lipid mediators in patients with AERD. Evidence for mast cell activation and degranulation during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge in patients with AERD also includes demonstrable elevations in mast cell tryptase and histamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/14,25\">",
"     14,25",
"    </a>",
"    ]. In addition, H1 antihistamines blunt the nasal and ocular reactions to aspirin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other areas of investigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in complement proteins between asthmatics with and without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitivity were revealed using proteomics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/44\">",
"     44",
"    </a>",
"    ]. A small case-control study examined changes in expression of plasma proteins in six aspirin-sensitive and six aspirin-tolerant asthmatics at baseline and after aspirin challenge, compared to control patients without asthma. Baseline differences were detected in complement proteins, apolipoproteins, and albumin complexed with myristic acid, with significant up and down-regulation of these proteins after aspirin challenge. In particular, patients with AERD had higher levels of C3a and C4a than tolerant patients at baseline, with levels that correlated to changes in FEV1 during challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AERD can often be made clinically when all three of the conditions that characterize AERD are present. A clinical diagnosis may be more difficult in patients with isolated asthma or chronic rhinosinusitis with nasal polyposis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical history of NSAID reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;When questioning a patient about adverse reactions to NSAIDs, it is helpful to describe the symptoms of pseudoallergic reactions, as patients may occasionally recognize the association for the first time. NSAID sensitivity is an acquired condition, and the symptoms following NSAID ingestion are similar to flares in the underlying conditions, so patients who were accustomed to taking these medications without difficulty often do not recognize the connection for some time. Conversely, patients may have taken NSAID during a respiratory infection or other illness and attributed respiratory symptoms to the medication, when in fact there was no cause and effect relationship.",
"   </p>",
"   <p>",
"    Some patients with asthma were empirically told to avoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and have not taken NSAIDs for a period of years. Studies in which NSAID intolerance was diagnosed by challenge have reported higher rates among the general asthmatic population compared to those that rely on history alone, so a challenge should be considered if AERD is suspected and the patient has been avoiding NSAIDs empirically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the clinical history suggests a reaction to an NSAID, the clinician should then attempt to determine if the patient has reacted to more than one COX-1 inhibiting NSAID. The patient should be questioned about any NSAID use SUBSEQUENT TO the first recognized reaction. NSAID ingestions BEFORE the first reaction are not relevant, since NSAID sensitivity is acquired, as reviewed previously. However, there is no evidence that previous NSAID ingestion is required in order to develop NSAID sensitivity. In patients with asthma and significant rhinosinusitis in which a careful history is taken, there is an 80 percent likelihood of having a positive oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge with a history of a single NSAID reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/45\">",
"     45",
"    </a>",
"    ]. This increases to 90 percent with a history of two NSAID reactions by history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indications for aspirin challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    challenge is the only way to diagnose NSAID sensitivity definitively. Definitive diagnosis is important for research protocols involving AERD patients. In contrast, aspirin challenge is only indicated for clinical purposes if the patient has a specific need for regular NSAID therapy (ie, NSAIDs for rheumatologic disease, aspirin for cardiovascular disease, or aspirin for treatment of AERD), in which case challenge is often performed as part of a desensitization protocol.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    challenges are generally performed orally in the United States. In other areas (eg, Europe) a liquid lysyl-acetylsalicylic acid derivative is available for diagnostic aspirin challenge. This can be administered either as an intranasal or bronchial challenge, although inhaled administration is not adequate for desensitization.",
"   </p>",
"   <p>",
"    In preparation for oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge or desensitization, patients with suspected AERD are usually pretreated with leukotriene modifying agents (LTMAs), as these medications have been shown to dramatically reduce the severity of pulmonary reactions during the procedure. LTMAs dramatically reduce the pulmonary symptoms, although nasal and ocular symptoms are still apparent in most patients, such that the outcome of challenge should be apparent to the experienced clinician. Antihistamines are also withheld for a week prior to the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    challenges are usually performed by allergy or pulmonary specialists with the expertise to manage any resultant symptoms, and in settings equipped with the necessary medications, equipment, and support staff. Protocols for aspirin challenge in patients with AERD are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26006?source=see_link\">",
"     \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of AERD involves treatment of the patient's asthma, medical and surgical management of chronic rhinosinusitis, and either avoidance of all COX-1 inhibiting NSAIDS, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    desensitization followed by daily aspirin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Asthma therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;National and international guidelines for asthma management apply to patients with AERD, except that leukotriene modifying agents (LTMAs) are administered in most cases to improve both pulmonary and sinonasal symptoms. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Leukotriene modifying agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Asthma management utilizing a step-wise approach is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Therapy for chronic rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical and surgical management of chronic rhinosinusitis with nasal polyposis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Leukotriene modifying agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukotriene modifying agents should be part of the management of all patients with AERD. Both inhibitors of leukotriene synthesis (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/33,46\">",
"     33,46",
"    </a>",
"    ] and leukotriene receptor antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    ) are effective in AERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/34,35,47,48\">",
"     34,35,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies demonstrate that the addition of a leukotriene-modifying agent to pre-existing therapy improves respiratory tract symptoms in patients with AERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/15,46,47\">",
"     15,46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial evaluated the effect of six weeks of treatment with the 5-LO inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"       zileuton",
"      </a>",
"      (600 mg, 4 times daily) in 40 patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -sensitive asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/46\">",
"       46",
"      </a>",
"      ]. Existing therapy was continued, which included medium to high doses of inhaled (average daily dose &gt;1000 micrograms of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      ) or oral glucocorticoids (4 to 25 mg daily) for all but one patient. The addition of zileuton, compared to placebo, resulted in both immediate and ongoing improvement in pulmonary function and lower use of short-acting beta agonists for symptom relief. Zileuton also alleviated nasal symptoms, including rhinorrhea, congestion, and impaired sense of smell. Furthermore, zileuton produced a small reduction of bronchial hyperresponsiveness to histamine.",
"     </li>",
"     <li>",
"      A subsequent randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      to placebo in 80 patients with asthma and NSAID intolerance, the majority of whom required inhaled or oral glucocorticoids to control their symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/47\">",
"       47",
"      </a>",
"      ]. Four weeks of treatment with montelukast was associated with a 10 percent increase in FEV1, higher morning peak flow rates, decreased use of rescue medications, and a significant improvement in asthma quality of life scores. The montelukast group also experienced 54 percent fewer asthma exacerbations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most clinicians prescribe oral leukotriene antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    ) initially, since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    requires monitoring of liver function tests and is therefore less convenient. If patients do not respond with clinical improvement, then zileuton may be added or substituted. Zileuton is currently available in a twice-daily preparation (1200 mg orally, twice daily). It should be noted that the simultaneous use of zileuton and a leukotriene receptor antagonist has not been formally studied. The rationale for combination therapy is based upon studies demonstrating that patients with AERD demonstrate elevated cysLT levels and receptor numbers, as well as upregulation of 5-LO. Thus, combination therapy may address these abnormalities more completely.",
"   </p>",
"   <p>",
"    We typically treat all patients with documented AERD with a minimum of a leukotriene receptor antagonist. This should address the underlying pathophysiology, and also protect them from severe exacerbations due to accidental NSAID exposure.",
"   </p>",
"   <p>",
"    The general use of leukotriene modifying agents in asthma is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     NSAID avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AERD should avoid all NSAIDs that inhibit COX-1 (",
"    <a class=\"graphic graphic_table graphicRef51209 \" href=\"mobipreview.htm?34/7/34939\">",
"     table 1",
"    </a>",
"    ), unless they have been desensitized to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Patients with AERD usually tolerate the following alternatives for the treatment of pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation, although exquisitely sensitive patients may even react to the agents listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      NSAIDs with very weak COX-1 inhibitory properties (eg, non-acetyl salicylates such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5350?source=see_link\">",
"       salsalate",
"      </a>",
"      and others)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      (at doses up to 650 mg; as many as 20 percent of AERD patients will react to a dose of 1000 mg)",
"     </li>",
"     <li>",
"      Highly selective COX-2 inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of these alternative agents in patients with AERD is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=see_link&amp;anchor=H18#H18\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Types 1 to 4 - treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Aspirin desensitization and aspirin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all AERD patients can be successfully desensitized to ASA. The mechanism through which ASA desensitization alters a patient's response to NSAIDs has not been proven, although one theory proposes that desensitization and subsequent daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    treatment reduces interleukin-4 (IL-4)-induced expression of leukotrienes by inhibiting the transcription factor STAT-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39944/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protocol for desensitization is essentially a continuation of the challenge procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26006?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnostic challenge and desensitization protocols for NSAID reactions\", section on 'Desensitization for pseudoallergy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are successfully desensitized to ASA can then safely ingest other COX-1 inhibiting NSAIDs. Once the patient has been desensitized, they must continue to take",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or another NSAID daily, in order to maintain the desensitized state. However, only aspirin (not other NSAIDS) has been shown specifically to be useful in slowing the regrowth of nasal polyps and improving asthma symptoms over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    therapy should be considered for patients with AERD and the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasal polyposis that is worsening despite leukotriene modifying agents, topical glucocorticoids, and other appropriate therapies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link\">",
"       \"Management of chronic rhinosinusitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory conditions requiring daily NSAID therapy.",
"     </li>",
"     <li>",
"      Atherosclerotic",
"      <span class=\"nowrap\">",
"       heart/vascular",
"      </span>",
"      disease requiring the antiplatelet effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Recurrent headaches or other conditions requiring intermittent use of NSAIDs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1811851\">",
"    <span class=\"h3\">",
"     Efficacy and dosing of aspirin for AERD treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in treating upper and lower airway disease in patients with AERD and the dosing of aspirin in this setting are reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18281?source=see_link&amp;anchor=H14035446#H14035446\">",
"     \"Aspirin exacerbated respiratory disease: NSAID challenge and desensitization\", section on 'Efficacy of aspirin therapy in AERD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      exacerbated respiratory disease (AERD) describes patients with asthma and chronic rhinosinusitis with nasal polyposis, who experience acute respiratory tract symptoms following the ingestion of aspirin or other NSAIDs. AERD affects 5 to 20 percent of all patients with asthma. Reactions to NSAIDs typically begin 30 minutes to 3 hours after ingestion, and present as a sudden worsening of asthma and nasal congestion, sometimes accompanied by other symptoms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology of AERD involves acquired perturbations in arachidonic acid metabolism and a resulting imbalance between proinflammatory and antiinflammatory mediators, leading to chronic airway inflammation. The pharmacologic action of COX-1-inhibiting NSAIDs acutely exacerbates this imbalance, and also results in mast cell activation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A working diagnosis of AERD is usually made clinically based upon the presence of the characteristic component disorders (ie, asthma, chronic rhinosinusitis with nasal polyposis, and a history of NSAID reactions). Definitive diagnosis requires",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      challenge, although this degree of diagnostic precision is rarely needed outside of research protocols. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26006?source=see_link\">",
"       \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with AERD require guideline-based therapy for asthma and medical and surgical management of chronic rhinosinusitis with nasal polyposis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"       \"An overview of asthma management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link\">",
"       \"Management of chronic rhinosinusitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exacerbated respiratory disease and moderate to severe asthma, we recommend adding a leukotriene modifying agent to their other asthma therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We usually begin with a leukotriene receptor antagonist (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      ). If there is no clinical improvement, we add or substitute the 5-LO inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"       zileuton",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Leukotriene modifying agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with AERD and nasal symptoms despite other therapies, we recommend a leukotriene modifying agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Leukotriene modifying agents'",
"      </a>",
"      above.) Patients with AERD should avoid all NSAIDs that inhibit COX-1 (",
"      <a class=\"graphic graphic_table graphicRef51209 \" href=\"mobipreview.htm?34/7/34939\">",
"       table 1",
"      </a>",
"      ), unless they have been desensitized to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H22\">",
"       'NSAID avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      desensitization followed by daily aspirin therapy should be considered in patients with AERD and any of the following disorders. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Indications'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nasal polyposis that is worsening despite intranasal glucocorticoids and other appropriate therapies.",
"     </li>",
"     <li>",
"      Inflammatory conditions requiring daily NSAID therapy.",
"     </li>",
"     <li>",
"      Atherosclerotic",
"      <span class=\"nowrap\">",
"       heart/vascular",
"      </span>",
"      disease requiring the antiplatelet effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Recurrent headaches or other conditions requiring intermittent use of NSAIDs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      desensitization is usually performed by allergists or pulmonologists with expertise in the technique and in a setting that is equipped to treat the range of reactions that may result. Following desensitization, patients must ingest NSAIDs daily to maintain the desensitized state, and can take different COX-1-inhibiting NSAIDs interchangeably. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Aspirin desensitization and aspirin therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18281?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease: NSAID challenge and desensitization\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/1\">",
"      Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/2\">",
"      Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/3\">",
"      Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/4\">",
"      Berkes EA. Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clin Rev Allergy Immunol 2003; 24:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/5\">",
"      Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/6\">",
"      Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/7\">",
"      Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/8\">",
"      Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/9\">",
"      Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/10\">",
"      Weber RW, Hoffman M, Raine DA Jr, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979; 64:32.",
"     </a>",
"    </li>",
"    <li>",
"     Shore SA, Austen KF, Drazen JM. Lung biology in health and disease: Lung cell biology. In: Eicosanoids and the lung, L'Enfant C, Massaro D (Eds), Marcel Dekker, New York 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/12\">",
"      Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/13\">",
"      Dahl&eacute;n B. Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med 2000; 161:S137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/14\">",
"      Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/15\">",
"      Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/16\">",
"      Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992; 119:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/17\">",
"      Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988; 137:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/18\">",
"      Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999; 104:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/19\">",
"      Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol 2009; 124:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/20\">",
"      Guilemany JM, Roca-Ferrer J, Mullol J. Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis. Curr Allergy Asthma Rep 2008; 8:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/21\">",
"      Stevenson DD, Zuraw BL. Pathogenesis of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/22\">",
"      Cai Y, Bjermer L, Halstensen TS. Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am J Respir Cell Mol Biol 2003; 29:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/23\">",
"      Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/24\">",
"      Nasser S, Christie PE, Pfister R, et al. Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 1996; 51:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/25\">",
"      Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/26\">",
"      Adamjee J, Suh YJ, Park HS, et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 2006; 209:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/27\">",
"      Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/28\">",
"      Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/29\">",
"      Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/30\">",
"      Sanak M, Levy BD, Clish CB, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000; 16:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/31\">",
"      Gaber F, Daham K, Higashi A, et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/32\">",
"      Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012; 119:3790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/33\">",
"      Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/34\">",
"      Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&amp;F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/35\">",
"      Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/36\">",
"      Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999; 160:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/37\">",
"      Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000; 161:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/38\">",
"      Pierzchalska M, Szab&oacute; Z, Sanak M, et al. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003; 111:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/39\">",
"      Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/40\">",
"      Ying S, Meng Q, Scadding G, et al. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 2006; 117:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/41\">",
"      Corrigan CJ, Napoli RL, Meng Q, et al. Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma. J Allergy Clin Immunol 2012; 129:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/42\">",
"      Babu KS, Salvi SS. Aspirin and asthma. Chest 2000; 118:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/43\">",
"      Mastalerz L, Sanak M, Gawlewicz-Mroczka A, et al. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 2008; 63:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/44\">",
"      Lee SH, Rhim T, Choi YS, et al. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med 2006; 173:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/45\">",
"      Williams AN, Simon RA, Woessner KM, Stevenson DD. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol 2007; 120:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/46\">",
"      Dahl&eacute;n B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/47\">",
"      Dahl&eacute;n SE, Malmstr&ouml;m K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/48\">",
"      Lee DK, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J 2004; 24:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/49\">",
"      Steinke JW, Culp JA, Kropf E, Borish L. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol 2009; 124:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39944/abstract/50\">",
"      Katial RK, Strand M, Prasertsuntarasai T, et al. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 2010; 126:738.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 520 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7C479FB97E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39944=[""].join("\n");
var outline_f39_0_39944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PSEUDOALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arachidonic acid metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - 5-lipoxygenase pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cyclooxygenase pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abnormalities in AERD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Involvement of mast cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other areas of investigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical history of NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indications for aspirin challenge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Protocols",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Asthma therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Therapy for chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Leukotriene modifying agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NSAID avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Aspirin desensitization and aspirin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1811851\">",
"      - Efficacy and dosing of aspirin for AERD treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/520|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/17/28957\" title=\"figure 1\">",
"      Aspirin provocation in AIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/11/24765\" title=\"figure 2\">",
"      Leukotriene synthesis AERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/12/16590\" title=\"figure 3\">",
"      Prostaglandin syn AERD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/520|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/7/34939\" title=\"table 1\">",
"      Aspirin NSAID and asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18281?source=related_link\">",
"      Aspirin exacerbated respiratory disease: NSAID challenge and desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26006?source=related_link\">",
"      Diagnostic challenge and desensitization protocols for NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_0_39945="Sudden cardiac arrest and death in children";
var content_f39_0_39945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sudden cardiac arrest and death in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39945/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39945/contributors\">",
"     Stuart Berger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39945/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39945/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39945/contributors\">",
"     Martin I Lorin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39945/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/0/39945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H192520686\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in children and adolescents are relatively rare. However, because these are unexpected devastating conditions, concerted efforts have been made to continue to find evidence-based strategies that will prevent these events in a cost-effective manner.",
"   </p>",
"   <p>",
"    The incidence, etiology, and prodromal signs of SCA in children and adolescents will be reviewed here. In addition, the role of screening to prevent pediatric SCA and the management of individuals with SCA will also be discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192520693\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of sudden cardiac arrest (SCA) for adolescent and young adults ranges from 0.5 to 20 per 100,000 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. A retrospective study from the state of Washington using population-based data from a county emergency medical service (EMS) reported an overall incidence of SCA of 2.28 per 100,000 person-years for individuals between 0 to 35 years of age from 1980 to 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6\">",
"     6",
"    </a>",
"    ]. In this series of 361 SCA cases, reported age-based incidences for individuals between 0 to 2 years, 3 to 13 years, and 14 to 25 years were 2.1, 0.61, and 1.44 cases per 100,000 person-years, respectively. Survival rates following SCA also varied by age with rates of 27, 40, and 37 percent for patients between 0 to 2 years, 3 to 13 years, and 14 to 25 years, respectively. Survival increased over the course of the study from 13 percent between 1980 and 1989 to 40 percent between 2000 and 2009. The authors attributed the rise in survival during the study period to improvements in the community-based EMS and changes in resuscitation protocols.",
"   </p>",
"   <p>",
"    In the above study, cases of sudden infant death syndrome (SIDS) were excluded because a cardiac cause could not be confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6\">",
"     6",
"    </a>",
"    ]. However, in several case series of SIDS, about 10 percent of deaths were reported to be caused by cardiac channel defects resulting in arrhythmias. As a result, the incidences of SCA and SCD in children less than two years of age were likely to be underestimated in this study. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=see_link&amp;anchor=H18#H18\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have reported a higher risk (2 to 2.5 times greater) of SCA during athletic",
"    <span class=\"nowrap\">",
"     competition/exercise",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/7\">",
"     7",
"    </a>",
"    ]. In the above study from Washington state, 25 percent of SCA occurred within one hour of exercise in the cases (n = 302) in which the relationship with exercise could be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the Centers for Disease Control and Prevention estimates that about 2000 individuals younger than 25 years of age will die of SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the true incidence of pediatric SCA remains unknown. A prospective mandatory registry, which may be established in the future, would be helpful in determining the prevalence of SCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192520700\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) are broad. In the previously discussed study from the state of Washington, the 360 cases were divided into the following categories of cardiac disease with their relative frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coronary artery disease (29 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary arrhythmia (electrical conduction defects) (22 percent), including long QT and Wolff-Parkinson-White syndromes (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features of congenital long QT syndrome\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=see_link&amp;anchor=H10#H10\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiomyopathic (20 percent), including hypertrophic cardiomyopathy, dilated cardiomyopathy, and myocarditis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30777?source=see_link\">",
"       \"Definition and classification of the cardiomyopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link&amp;anchor=H274524#H274524\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital cardiac disease (15 percent), such as tetralogy of Fallot, hypoplastic left heart syndrome, and transposition of the great arteries (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=see_link\">",
"       \"Cardiac causes of cyanosis in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other cardiac disorders (8 percent), including coronary arteritis, anomalous origin of coronary arteries, aortic dissection, and mitral valve prolapse. However, the relationship between mitral valve prolapse and sudden cardiac disease is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17719?source=see_link&amp;anchor=H3#H3\">",
"       \"Arrhythmic complications of mitral valve prolapse\", section on 'Sudden cardiac death'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=see_link\">",
"       \"Congenital and pediatric coronary artery abnormalities\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unspecified cardiac disease (7 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cause of death varied by age as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients two years of age or younger, congenital heart disease (84 percent) was the predominant cause of SCA. Primary arrhythmia (8 percent) and myocarditis (4 percent) were much less common causes of SCA in this age group. However, this study did not include patients diagnosed with sudden infant death syndrome (SIDS), in whom 10 percent of death is caused by a primary arrhythmia due to a genetic electrical conduction defect. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=see_link&amp;anchor=H18#H18\">",
"       \"Sudden infant death syndrome: Risk factors and risk reduction strategies\", section on 'Genetic factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients between 3 and 13 years of age, there was no dominant cause of SCA. Etiologies included congenital heart disease (21 percent), hypertrophic cardiomyopathy (18 percent), long QT syndrome (14 percent), primary arrhythmia (11 percent), and mitral valve prolapse (7 percent).",
"     </li>",
"     <li>",
"      For patients between 14 and 24 years of age, there was no dominant cause of SCA. Etiologies included primary arrhythmia (23 percent), congenital heart disease (23 percent), dilated cardiomyopathy (14 percent), long QT syndrome (8 percent), myocarditis (4 percent), hypertrophic cardiomyopathy (2 percent), and other nonspecified cardiac causes (26 percent).",
"     </li>",
"     <li>",
"      Coronary artery disease as a cause of SCA was only seen in patients between 25 and 35 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study has shown that the most common cause of SCD in competitive athletic adolescents was hypertrophic cardiac myopathy, accounting for one-third of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268779676\">",
"    <span class=\"h2\">",
"     Genetic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular research has increasingly demonstrated that many of the underlying cardiac diseases causing SCA and SCD are due to genetic disorders. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiomyopathy, including hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and restrictive cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link\">",
"       \"Genetics of hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link&amp;anchor=H6#H6\">",
"       \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Genetics'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39576?source=see_link\">",
"       \"Genetics of dilated cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23207?source=see_link&amp;anchor=H3#H3\">",
"       \"Idiopathic restrictive cardiomyopathy\", section on 'Familial disease'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ion channelopathies, such as congenital long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28681?source=see_link\">",
"       \"Genetics of congenital and acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link&amp;anchor=H12#H12\">",
"       \"Brugada syndrome\", section on 'Genetics'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/61/19417?source=see_link&amp;anchor=H1561601157#H1561601157\">",
"       \"Short QT syndrome\", section on 'Genetic basis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37641?source=see_link&amp;anchor=H3#H3\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Catecholaminergic polymorphic VT'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Familial Wolff-Parkinson-White syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link&amp;anchor=H7#H7\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Familial WPW'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the previously discussed study from Washington, genetic cardiac disorders accounted for 20 percent of all SCA cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6\">",
"     6",
"    </a>",
"    ]. In smaller case series in which an initial etiology is not identified, genetic cardiac conditions were identified in 35 percent to half of the families in which there was an affected child or adolescent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results highlight the importance of genetic screening in families in which there is a SCD or SCA. In addition, these data also emphasize the need to obtain a complete family history to determine if any close relative died unexpectedly and decide if further evaluation is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780323923\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immediate cause of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) appears to be a life-threatening and often lethal ventricular tachyarrhythmia (ie, ventricular fibrillation or pulseless ventricular tachycardia) that results in cardiac collapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. These arrhythmias may be short in duration and self-terminating, and previous episodes may have resulted in syncope, presyncope, or seizure-like activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15897?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of wide QRS complex tachycardia in children\", section on 'Ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268779936\">",
"    <span class=\"h1\">",
"     WARNING SIGNS AND SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sudden cardiac arrest (SCA) is often the initial presenting event, retrospective studies have shown that warning signs or symptoms (eg, chest pain, fatigue, and",
"    <span class=\"nowrap\">",
"     syncope/lightheadedness)",
"    </span>",
"    were noted by at least 40 and up to 70 percent of affected individuals prior to SCA or sudden cardiac death (SCD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This was illustrated in a review of the literature that reported about one-half of children and young adults (below 40 years of age) who died suddenly from cardiac cases had prodromal symptoms. The most common symptoms were chest pain and actual or near syncope. Other symptoms included dizziness, palpitations, or dyspnea. There was also a reported wide range (25 to 61 percent) of a family history of premature unexpected death.",
"   </p>",
"   <p>",
"    In a study based on completed surveys from 86 of an initial cohort of 146 families of children and young adults (below 30 years of age) with SCA, 70 percent of individuals were reported by their parents to have had at least one prior cardiovascular symptom, which first occurred on average 30 months before SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/13\">",
"     13",
"    </a>",
"    ]. Fatigue (44 percent) and near",
"    <span class=\"nowrap\">",
"     syncope/lightheadedness",
"    </span>",
"    (30 percent) were the two most common complaints. In addition, 24 percent of SCA victims had one or more events (average number 2.6) of syncope or unexplained seizure-like activity that remained undiagnosed before SCA. In about 40 percent of cases, the symptom was brought to the attention of the child&rsquo;s physician, and 27 percent of families reported a history of a family member who had suffered SCD before 50 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780323955\">",
"    <span class=\"h2\">",
"     Electrocardiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiographic (ECG) study is often performed in children who present with prodromal symptoms or as a part of a preparticipation sport evaluation. Although similar information is not available in children, it appears that benign ECG findings are common in young adults (especially trained athletes) and do not require further evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a study of 658 collegiate athletes (age range 18 to 22 years) that reported that 62 percent of men and 32 percent of women had abnormal ECGs, but only 10 percent had findings that warranted further testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/14\">",
"     14",
"    </a>",
"    ]. In most cases, ECG findings were benign and expected to be observed in trained athletes. These training-related ECG findings included isolated increased QRS voltage, early repolarization (ST elevation in precordial leads V3 through V6 with an elevated J point and a peaked upright T wave), and evidence of increased vagal tone (manifested as sinus bradycardia, and increased PR intervals up to 300 ms). ECG findings in 29 cases were classified as distinctly abnormal that required further evaluation.",
"   </p>",
"   <p>",
"    ECG findings that warrant further evaluation (such as detailed history and physical examination, echocardiography, or genetic testing) include the following (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12409?source=see_link&amp;anchor=H37#H37\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\", section on 'Abnormal ECG findings'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Q waves greater than 3 mm in depth",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      40 ms duration in at least 2 leads are characteristic findings for hypertrophic cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link&amp;anchor=H612576623#H612576623\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Electrocardiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Conduction delay with a QRS duration greater than or equal to 120 ms in adults, greater than 100 ms in children 4 to 16 years of age, and greater than 90 ms in children less than 4 years of age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=see_link&amp;anchor=H618500#H618500\">",
"       \"Left bundle branch block\", section on 'Electrocardiographic findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15897?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes of wide QRS complex tachycardia in children\", section on 'Supraventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial abnormalities defined as P wave amplitude greater than 2.5 mm for right atrial abnormality. Criteria for left atrial abnormalities consist of a negative component of the P wave in V1 or V2 of 40 ms duration and 1 mm amplitude, and a total P-wave duration greater than 120 ms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27204?source=see_link&amp;anchor=H1#H1\">",
"       \"ECG tutorial: Chamber enlargement and hypertrophy\", section on 'Left atrial abnormality/enlargement'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27204?source=see_link&amp;anchor=H2#H2\">",
"       \"ECG tutorial: Chamber enlargement and hypertrophy\", section on 'Right atrial abnormality/enlargement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ST elevation more than 2 mm, ST depression greater than 0.5 mm, and T wave inversions can be seen in patients with myocardial ischemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=see_link\">",
"       \"ECG tutorial: ST and T wave changes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      QT abnormalities are suggestive of ion channel abnormalities either due to mutations or exposure to specific medications (",
"      <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"mobipreview.htm?26/24/27008\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link\">",
"       \"Clinical features of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"       \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/61/19417?source=see_link&amp;anchor=H1561601157#H1561601157\">",
"       \"Short QT syndrome\", section on 'Genetic basis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Delta wave (slurring of the initial QRS and a short PR interval (&lt;120 ms) is associated with Wolff-Parkinson-White syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef75578 \" href=\"mobipreview.htm?34/55/35706\">",
"       waveform 2",
"      </a>",
"      )). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link&amp;anchor=H13260510#H13260510\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Electrocardiographic (ECG) findings'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H798045419\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of sudden cardiac arrest (SCA), prodromal signs or symptoms including chest pain,",
"    <span class=\"nowrap\">",
"     syncope/presyncope,",
"    </span>",
"    dyspnea, and seizure-like activity are often reported. These nonspecific symptoms are frequently thought to be due to other conditions, which can be differentiated from the underlying cardiac disorder by clinical manifestations or tests.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syncope &ndash; In children, the most likely cause of syncope or presyncope is neurocardiogenic syncope, also referred to as vasovagal syncope. Vasovagal syncope is often triggered by pain or fear and is commonly accompanied by premonitory symptoms before collapse, such as lightheadedness, dizziness, diaphoresis, nausea, and tunnel vision. In contrast, syncope associated with SCA generally occurs without warning, during exercise, or is associated with chest pain or palpitations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other less common causes of pediatric syncope include migraine headaches, seizures, and brain tumors. These conditions, like vasovagal syncope, are associated with prodromal symptoms, or in the case of seizures, a postictal state and incontinence. The causes and evaluation of pediatric syncope are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36007?source=see_link\">",
"     \"Causes of syncope in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11432?source=see_link&amp;anchor=H3#H3\">",
"     \"Emergent evaluation of syncope in children and adolescents\", section on 'Evaluation and decision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seizure &ndash; Seizures may be difficult to distinguish from SCA. The myoclonic movements due to cerebral hypoxia in patients with SCA generally occur after the initial collapse, whereas in individuals with seizures, body movements begin concurrently with loss of postural tone and collapse. However, this clinical distinction may be difficult to ascertain. As a result, we suggest that the evaluation of children with seizure-like activity include electrocardiography (ECG) and possibly an echocardiogram. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=see_link\">",
"       \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest pain &ndash; Chest pain is a common finding in children and generally is due to musculoskeletal conditions, such as costochondritis or trauma. In contrast, cardiac disease is an uncommon cause of chest pain. Chest pain is almost never present with patients with primary electrical disorders but is more likely to be present in patients with cardiomyopathies or abnormalities of the coronary arteries or aorta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11\">",
"       11",
"      </a>",
"      ]. Cardiac disease is more probable if chest pain occurs during exertion, is recurrent, or is accompanied with palpitations or syncope. A thorough history and physical examination generally distinguished cardiac disease from benign conditions that do not require further workup. Cardiac evaluation (eg, ECG or echocardiography) is warranted in patients with abnormal physical findings or with cardiorespiratory symptoms such as syncope, palpitations, and dyspnea. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=see_link&amp;anchor=H23#H23\">",
"       \"Approach to chest pain in children\", section on 'Description of chest pain'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=see_link&amp;anchor=H29#H29\">",
"       \"Approach to chest pain in children\", section on 'Examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise-induced wheezing &ndash; Exercise-induced bronchospasm may be present in patients with cardiomyopathies. These patients are generally unresponsive to bronchodilator therapy, which differentiates them from those with asthma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sudden cardiac death (SCD) should also be considered in cases of drowning victims and sudden infant death syndrome (SIDS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11\">",
"     11",
"    </a>",
"    ]. In these settings, it is important to review the family history to see if there are any family members who died unexpectedly before the age of 50 years to ascertain if further testing (including genetic screening) is indicated. (See",
"    <a class=\"local\" href=\"#H268779676\">",
"     'Genetic disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H798045536\">",
"    <span class=\"h1\">",
"     PREVENTIVE STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive strategies to reduce sudden cardiac death (SCD) are divided into primary and secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prevention screens and identifies the at-risk individual and provides treatment options that would prevent sudden cardiac arrest (SCA) and SCD.",
"     </li>",
"     <li>",
"      Secondary prevention for children with SCA is focused on successful resuscitation and prevention of death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268780265\">",
"    <span class=\"h2\">",
"     Primary prevention (screening)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871783333\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major issue in primary prevention revolves around whether there is a cost-effective screen to identify individuals with cardiac disorders that are associated with SCA. Screening is common in regular pediatric care and is designed to identify conditions that if untreated result in mortality or major sequelae, and for which there is&nbsp;an available cost-effective treatment. When deciding whether screening should be performed, the sensitivity, specificity, and cost of the screening test, and the potential benefits and harms of screening and intervention must be considered.",
"   </p>",
"   <p>",
"    Currently, data are lacking to recommend an optimal screening approach for primary prevention of SCA and SCD as there are many unresolved issues and questions that impact on the effectiveness of screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whom do we screen: Universal versus selective screening",
"     </li>",
"     <li>",
"      When do we screen: Infancy versus adolescence or throughout childhood",
"     </li>",
"     <li>",
"      How do we screen: Role of electrocardiography (ECG)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871783378\">",
"    <span class=\"h3\">",
"     Universal versus selective screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of SCA and SCD is low in the general pediatric population, and it is challenging to demonstrate the effectiveness of a universal screening program. As a result, screening has focused on select populations who are deemed to be at risk, such as competitive athletes. However, even in this selected group, the incidence of SCA is low, and the impact of screening for SCA and the optimal approach remain uncertain as evidence is conflicted and limited. These data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31318?source=see_link\">",
"     \"Screening to prevent sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871783385\">",
"    <span class=\"h3\">",
"     Age of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;If screening to detect children at-risk for SCA were to be performed, it needs to be performed multiple times throughout childhood, as the specific causes of SCA and their clinical manifestations vary during childhood. For example, early screening for primary electrical conduction defects (eg, long QT syndrome) would need to be performed within the first year of life to detect affected infants and young children at risk for SCD. In contrast, clinical manifestations of hypertrophic cardiomyopathy are not commonly observed until adolescence, and screening for this entity would not be effective before 12 years of age. (See",
"    <a class=\"local\" href=\"#H192520700\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Screening of first-degree relatives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871783392\">",
"    <span class=\"h3\">",
"     Method of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The method of screening is dependent on the choice of conditions to be identified, and the sensitivity and specificity of the test. So for example, the cost-benefit of ECG screening is dependent on the underlying condition and its prevalence, and the expertise of the interpretation of ECG findings. False-negative results with a screening ECG would be likely in patients with a coronary artery abnormality who usually have a normal ECG and in up to 20 percent of patients with long QT syndrome. The false-positive rates vary depending on the expertise of the person interpreting the ECG, as there are variations in findings based upon age and race in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/16\">",
"     16",
"    </a>",
"    ]. In particular, ECG, which has been proposed as a screening test in the newborn to detect primary conduction defects (eg, long QT syndrome), has a poor sensitivity and specificity in the first few days of life because of cardiac functional changes (right versus left-sided dominance) with the transition from intra- to extrauterine life, making interpretation challenging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of clinical data also does not allow a direct comparison in the cost effectiveness of different screening strategies with the exception of neonatal pulse oximetry screening. However, randomized trials are not feasible due the low prevalence rate of pediatric SCA. Studies using simulation modeling analysis have calculated the cost-benefits of different screening approaches in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These studies have preselected the age of screening, assumed rates of false-positive and false-negative results, and initiation and cost of treatment, if appropriate.",
"   </p>",
"   <p>",
"    Based on the following analyses, the addition of ECG does not appear to be cost-effective.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study, modeling analysis compared the following three approaches with screening at 14 years of age as part of a preparticipation evaluation of athletes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/17\">",
"       17",
"      </a>",
"      ]. This analysis assumed cardiology referral included ECG, and in 90 percent of cases, an echocardiogram.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History and physical examination",
"      <strong>",
"       only",
"      </strong>",
"      , with cardiac referral and ECG for any suspicious finding.",
"     </li>",
"     <li>",
"      History and physical examination. If the history and physical examination are negative for any suspicious finding, an ECG is performed. Cardiac referral is made if there is any suspicious finding (history, physical examination, and ECG).",
"     </li>",
"     <li>",
"      History, physical examination, and ECG. Cardiac referral was only made if there was a suspicious ECG finding.",
"      <br/>",
"      Compared to a history and physical examination alone, the cost incremental for adding an ECG was either $68,800 per quality-adjusted life year (QALY) for additional ECG if the history and physical examination were normal, or $37,700 per QALY for the universal addition of ECG to the preparticipation evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a second study, modeling analysis demonstrated a high cost to relative health benefit of a preparticipation evaluation of 14-year-old adolescents consisting of detailed history, physical examination, and ECG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/18\">",
"       18",
"      </a>",
"      ]. In this study, the simulation model projected the incremental cost per life-year saved for the addition of an ECG was $90,828 for three specific cardiac disorders (hypertrophic cardiac myopathy, Wolf-Parkinson-White syndrome, and long QT syndrome) that would be detected by ECG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results support the current recommendations from the American Heart Association (AHA) and the American Academy of Pediatrics (AAP) that currently available evidence suggests the most cost-effective initial screening for children and adolescents for cardiac disease is a detailed history and physical examination",
"    <strong>",
"     alone",
"    </strong>",
"    . The addition of ECG is",
"    <strong>",
"     not",
"    </strong>",
"    recommended as an initial screening test. (See",
"    <a class=\"local\" href=\"#H871783400\">",
"     'Societal recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For competitive athletes, including adolescents, there is controversy on the best approach for screening to prevent SCD. In the United States, screening based on history and physical examination alone is currently recommended. Screening to prevent SCD for competitive athletes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31318?source=see_link\">",
"     \"Screening to prevent sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In newborns, there is good evidence that universal screening with pulse oximetry during birth hospitalization is cost-effective for detecting critical congenital heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link&amp;anchor=H2707728#H2707728\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Pulse oximetry screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871783400\">",
"    <span class=\"h3\">",
"     Societal recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AHA and the AAP concurred that information is insufficient for evidence-based recommendation regarding screening for cardiac disorders associated with SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11,16,19\">",
"     11,16,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, based on the currently available data, the two American societies agree that there was no evidence that an ECG or any other cardiovascular screening program would reduce the incidence of SCD in the United States.",
"   </p>",
"   <p>",
"    The AAP policy statement emphasized the importance of the following points for pediatric care providers for primary prevention of SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recognize the warning signs and symptoms of SCA. (See",
"      <a class=\"local\" href=\"#H268779936\">",
"       'Warning signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain a comprehensive and accurate history of any family member who died unexpectedly before the age of 50 years.",
"     </li>",
"     <li>",
"      Use standardized preparticipation athletic evaluation to minimize unnecessary variation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/13/36058?source=see_link&amp;anchor=H12#H12\">",
"       \"The preparticipation sports examination in children and adolescents\", section on 'Evaluation forms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Refer any patient or family with known or suspected cardiac disorders to a pediatric cardiac center for further evaluation that may include ECG, echocardiography, exercise testing, and genetic testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871783553\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unlikely that any primary prevention program alone will prevent all episodes of SCD. Therefore, it is important to improve the survival rate of children with SCA. Poor outcome is related to prolonged periods of no cardiac output, in part because effective cardiopulmonary resuscitation is not performed. In the previously discussed study from the state of Washington, improved survival rate for children and young adults who suffered SCA was attributed in part to the publication of new resuscitative guidelines in 2005 and the presence of robust community-based emergency medical services (EMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study, the survival rate rose from 25 to 58 percent after the initiation of a single shock without rhythm reanalysis.",
"   </p>",
"   <p>",
"    Both the AHA and AAP support efforts to improve survival by early symptom recognition, the use of 911 EMS, effective bystander cardiopulmonary resuscitation (CPR), and deployment and use of automatic external defibrillators (AEDs) in the community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. These statements emphasize the need for community support to place AEDs in public places, and to teach effective bystander CPR and AEDs use. In particular, developing and implementing CPR-AED programs within schools have saved the lives of both students and adults who have had SCA in the school setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30041?source=see_link&amp;anchor=H11#H11\">",
"     \"Outcome of sudden cardiac arrest\", section on 'Bystander CPR'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25208?source=see_link&amp;anchor=H8#H8\">",
"     \"Automated external defibrillators\", section on 'AED allocation strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060379\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent sudden cardiac arrest (SCA) and sudden cardiac death (SCD), our approach is consistent with that of the American Heart Association (AHA) and the American Academy of Pediatrics (AAP) and includes both primary (screening) and secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11,16\">",
"     11,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060481\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the currently available evidence, we suggest that screening for cardiac diseases associated with SCA and SCD be performed using a detailed history and physical examination, and",
"    <strong>",
"     not",
"    </strong>",
"    include any initial testing (eg, electrocardiography [ECG]) with the possible exception of pulse oximetry in the newborn. Screening is performed during the initial birth hospitalization, routine child care visits, and preparticipation sports assessment. (See",
"    <a class=\"local\" href=\"#H268780265\">",
"     'Primary prevention (screening)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060510\">",
"    <span class=\"h3\">",
"     Newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good evidence that universal neonatal pulse oximetry improves the detection of newborn infants with critical congenital heart disease (CHD) who are at risk of dying suddenly in the first few weeks of life. However, there are challenges in implementing an effective screening program that ensures reliable and accurate screening and diagnosis of critical CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link&amp;anchor=H2707728#H2707728\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Pulse oximetry screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060556\">",
"    <span class=\"h3\">",
"     Routine healthcare visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there are changes regarding the history and physical examination of children who may be at risk for cardiac diseases associated with SCA, we concur with the AAP recommendation that cardiovascular assessment be performed throughout childhood during routine healthcare visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11\">",
"     11",
"    </a>",
"    ]. As examples, both patient and family histories change over time, and symptoms of some cardiac conditions (eg, hypertrophic cardiomyopathy) may not present until adolescence. Routine screening also includes the vast majority of children who do not participate in an organized sports program and who would be omitted in a selective screening approach based on preparticipation sports assessment.",
"   </p>",
"   <p>",
"    Although, the following questions have not been validated by outcome studies, expert opinion suggests that these historical features be included based on data from retrospective studies that have shown that half of children who experience SCA have prodromal warning signs and symptoms, and over a quarter have a history of a sudden and unexpected death of a family member before the age of 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11,13\">",
"     11,13",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H268779936\">",
"     'Warning signs and symptoms'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of syncope, near-syncope, or seizure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exercise-induced chest pain or shortness of breath",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of sudden unexpected, unexplained death in a family member before 50 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of cardiac disease associated with sudden death including hypertrophic cardiomyopathy, Marfan syndrome, arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, short QT syndrome, Brugada syndrome, or catecholaminergic polymorphic ventricular tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical findings suggestive of underlying cardiac disease include tachycardia, elevated blood pressure, and abnormal heart examination (eg, heart murmur), which are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12409?source=see_link&amp;anchor=H19#H19\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\", section on 'Physical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060608\">",
"    <span class=\"h3\">",
"     Preparticipation sports assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, a preparticipation sports assessment is the standard of care for children and adolescents who participate in an organized sport. The use of a standardized preparticipation assessment is endorsed by several major American medical societies, including the AAP, to ensure that all the important aspects of the history and physical examination are addressed. As noted above, because the risk of SCA appears to increase with exertion, this standardized evaluation includes a focused cardiovascular (CV) history and physical examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/13/36058?source=see_link&amp;anchor=H12#H12\">",
"     \"The preparticipation sports examination in children and adolescents\", section on 'Evaluation forms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Questions of importance in the CV history include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31318?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening to prevent sudden cardiac death in athletes\", section on 'Major society guidelines'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Past history of hypertension, cardiac murmur, high cholesterol, Kawasaki disease, or heart infection.",
"     </li>",
"     <li>",
"      Past history of syncope, near syncope, dizziness, angina, or palpitations during exercise. The athlete should be asked specifically if he or she has passed out; has nearly passed out; has felt lightheaded; or has had chest pain, an irregular heartbeat, or excessive, unexpected, or exceptional unexplained shortness of breath or fatigue during or after exercise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. True anginal pain, characterized by substernal, deep, pressure-like pain that radiates and is associated with dyspnea and causes the athlete to stop activity is unusual in adolescents. The presence of any of the above symptoms that cannot be explained (eg, by vasovagal presyncope) requires exclusion from participation in competitive sports pending cardiac evaluation, and the patient should also be counseled to avoid strenuous exercise until that evaluation is complete. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/13/36058?source=see_link&amp;anchor=H40#H40\">",
"       \"The preparticipation sports examination in children and adolescents\", section on 'Noninvasive cardiovascular evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of chest pain. Although chest pain is a common complaint in children and adolescents, characteristics that suggest an organic etiology and require further evaluation are onset less than 48 hours, associated fever or interrupted sleep, and abnormal findings on physical examination. This is in addition to warning signs of cardiac disease such as angina, palpitations, and syncope during exercise, discussed under cardiac screening.",
"     </li>",
"     <li>",
"      A history of unexplained seizure.",
"     </li>",
"     <li>",
"      A history of cardiac testing (eg, electrocardiogram, echocardiogram).",
"     </li>",
"     <li>",
"      Feeling tired or short of breath more quickly than peers during exercise that is not due to poor conditioning or exercise-induced bronchospasm.",
"     </li>",
"     <li>",
"      A family history of death from heart problems, unexpected or unexplained sudden death before age 50 years (including drowning, unexplained car accident, or sudden infant death syndrome [SIDS]).",
"     </li>",
"     <li>",
"      A family history of hypertrophic cardiomyopathy, Marfan syndrome, arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, short QT syndrome, Brugada syndrome, or catecholaminergic polymorphic ventricular tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39945/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A family history of a heart problem, pacemaker, or implanted defibrillator.",
"     </li>",
"     <li>",
"      A family history of unexplained fainting, unexplained seizures, or near drowning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination includes measurement of blood pressure and resting heart rate, and cardiac auscultation to assess rate and rhythm of the heart and detect any cardiac murmur. Physical findings suggestive of underlying cardiac disease include tachycardia, elevated blood pressure, and abnormal heart examination (eg, heart murmur), which are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12409?source=see_link&amp;anchor=H19#H19\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\", section on 'Physical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24488717\">",
"    <span class=\"h3\">",
"     Further evaluation and referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric patients with a historical or physical finding that is suggestive of cardiac disease should be referred to a pediatric cardiac center for further evaluation. The timing of referral is dependent on the clinical condition of the patient and the seriousness of the underlying diagnosis that may be suspected. Urgent referral or consultation with a pediatric cardiologist should occur in patients with or at risk for hemodynamic compromise and death due to suspected cardiac disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12409?source=see_link&amp;anchor=H2#H2\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\", section on 'Timing of referral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24489234\">",
"    <span class=\"h2\">",
"     Survivors of SCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive workup must be undertaken for the survivor of an SCA under the direction of a cardiologist with expertise in pediatric cardiac disease associated with SCA. The evaluation consists of a comprehensive history, family history, physical examination, ECG and echocardiogram (to detect any structural and functional abnormality). Additional testing should be guided by the results of the initial workup and includes a Holter ECG, an exercise stress test, cardiac magnetic resonance imaging (MRI),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrophysiologic (EP) testing. The decision to obtain genetic testing is based on test results, family, and the discretion of the treating cardiologist. First-degree relatives, including siblings and parents, should also be assessed. The studies that are done on the first-degree relatives will depend upon the diagnosis of the affected individual.",
"   </p>",
"   <p>",
"    In most cases of survivors of SCA, an implantable cardioverter-defibrillator is inserted to prevent SCD from recurrent episodes of arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24489265\">",
"    <span class=\"h2\">",
"     Victims of SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a child or adolescent dies unexpectedly, an assessment of the cardiac anatomy at the time of autopsy is critical. If the examining medical",
"    <span class=\"nowrap\">",
"     examiner/coroner",
"    </span>",
"    does not have a level of comfort in the intricacies of cardiac anatomy, consultation should be sought. Histologic examination should be included to detect any finding consist with cardiomyopathic conditions.",
"   </p>",
"   <p>",
"    If a cardiac anatomic explanation for the SCD episode is not found, a molecular autopsy should be performed including genetic testing. A very careful family history also should be obtained. Further assessment of first-degree relatives including siblings and parents is determined by the results of a careful evaluation of family history, autopsy, and genetic testing. These studies include ECG, echocardiogram, Holter ECG, and cardiac MRI, exercise stress test,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrophysiology (EP) testing.",
"   </p>",
"   <p>",
"    A genetic counselor is a key individual in helping the family deal with the complicated issues surrounding the unexpected death of the child and obtaining an accurate family pedigree that will aid in the diagnosis of the underlying cardiac defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24489289\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is extremely unlikely that any and all primary prevention programs alone will prevent all episodes of SCA. Therefore, we advocate community programs that increase public placement of AEDs, and teach effective bystander CPR and AEDs use. (See",
"    <a class=\"local\" href=\"#H871783553\">",
"     'Secondary prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24489528\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168191245\">",
"    <span class=\"h2\">",
"     Epidemiology, etiology, and prodromal symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric sudden cardiac arrest (SCA) is relatively rare, with reported incidence of about 2 per 100,000 person-years. In the United States, survival following SCA has improved, with an estimated current survival rate of about 40 percent for children and young adults (0 to 35 years of age). (See",
"      <a class=\"local\" href=\"#H192520693\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The underlying cardiac disease associated with SCA varies with age. (See",
"      <a class=\"local\" href=\"#H192520700\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For children two years or younger, congenital heart disease is the predominant cause of SCA.",
"     </li>",
"     <li>",
"      For older children and adolescents, there is no dominant cause of SCA. Cardiac disorders include congenital heart disease, primary arrhythmias due to conduction defects, cardiomyopathies, myocarditis, and mitral valve prolapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic cardiac diseases associated with SCA and sudden cardiac death (SCD) include cardiomyopathies (hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, and restrictive cardiomyopathy), ion channelopathies resulting in conduction defects (congenital long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia), and familial Wolff-Parkinson-White syndrome. (See",
"      <a class=\"local\" href=\"#H268779676\">",
"       'Genetic disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The immediate cause of SCA and SCD appears to be a life-threatening and often lethal ventricular tachyarrhythmia (ie, ventricular fibrillation or pulseless ventricular tachycardia) that results in cardiac collapse. (See",
"      <a class=\"local\" href=\"#H780323923\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although SCA is often the initial presenting event, warning signs or symptoms (eg, chest pain, fatigue, seizures, and",
"      <span class=\"nowrap\">",
"       syncope/lightheadedness)",
"      </span>",
"      are noted in at least 40 percent and up to 70 percent of individuals prior to SCA. In at least one-quarter of cases, there is a history of a family member who suffered sudden unexpected cardiac death before 50 years of age. (See",
"      <a class=\"local\" href=\"#H268779936\">",
"       'Warning signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of SCA is broad because the prodromal signs and symptoms of SCA are nonspecific. Other disorders that need to be distinguished from an underlying cardiac disease include vasovagal syncope, migraine headaches, seizures, musculoskeletal conditions that present with chest pain, asthma, near-drowning, and sudden infant death syndrome (SIDS). (See",
"      <a class=\"local\" href=\"#H798045419\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168191266\">",
"    <span class=\"h2\">",
"     Prevention of SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive strategies to reduce SCD include primary screening to identify and manage at-risk individuals, and secondary prevention with successful resuscitation of individuals with SCA. (See",
"    <a class=\"local\" href=\"#H798045536\">",
"     'Preventive strategies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1060379\">",
"     'Our approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the lack of sound data, the optimal screening approach for primary prevention of SCA remains uncertain. Unresolved issues include who to screen, when to screen, and the best methodology of screening. (See",
"      <a class=\"local\" href=\"#H268780265\">",
"       'Primary prevention (screening)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on the currently available evidence, we suggest screening for cardiac diseases associated with SCA and SCD be performed using a detailed history and physical examination, which does",
"      <strong>",
"       not",
"      </strong>",
"      include any initial testing (eg, electrocardiography [ECG]) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The one exception is universal pulse oximetry screening for critical congenital heart disease in the newborn. (See",
"      <a class=\"local\" href=\"#H1060379\">",
"       'Our approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H871783400\">",
"       'Societal recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following screening approach, which is consistent with the recommendations of the American Heart Association (AHA) and the American Academy of Pediatrics (AAP) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H1060379\">",
"       'Our approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H871783400\">",
"       'Societal recommendations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      During the initial birth hospitalization, adding universal pulse oximetry (with appropriate quality control and infrastructure) to a comprehensive history and physical examination to increase the detection rate of critical congenital heart disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link&amp;anchor=H2707728#H2707728\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Pulse oximetry screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      During each routine child care visit, the following aspects of the history should be included: history of syncope, near-syncope, or seizure; exercise-induced chest pain or shortness of breath; a history of sudden unexpected, unexplained death in a family member before 50 years of age; and a family history of cardiac disease associated with sudden death (eg, long QT syndrome). (See",
"      <a class=\"local\" href=\"#H1060556\">",
"       'Routine healthcare visits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children and adolescents who participate in an organized sport should undergo a preparticipation evaluation that includes a cardiovascular (CV) assessment. Questions of particular importance in the CV history include past history of hypertension or cardiac murmur; past history of syncope, near syncope, angina, or palpitations during exercise, or dizziness associated with any of these; a history of chest pain; and family history of CV disease (especially SCD at younger than 50 years of age), hypertrophic cardiomyopathy, dilated cardiomyopathy, long QT syndrome, Marfan syndrome, or clinically important arrhythmias. (See",
"      <a class=\"local\" href=\"#H1060608\">",
"       'Preparticipation sports assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination includes measurement of blood pressure and resting heart rate, and cardiac auscultation to assess rate and rhythm of the heart and detect any cardiac murmur. Findings suggestive of underlying cardiac disease include tachycardia, elevated blood pressure, and abnormal heart examination (eg, heart murmur). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12409?source=see_link&amp;anchor=H19#H19\">",
"       \"Suspected heart disease in infants and children: Criteria for referral\", section on 'Physical findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with either a historical or physical finding suggestive of an underlying cardiac disorder should be further evaluated (eg, ECG) or referred to a cardiac specialist with pediatric expertise. (See",
"      <a class=\"local\" href=\"#H24488717\">",
"       'Further evaluation and referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend a comprehensive evaluation of pediatric survivors of SCA to identify and treat the underlying cardiac condition under the direction of a cardiologist with expertise in pediatric cardiac disease (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The initial assessment includes complete history, family history, physical examination, ECG, and echocardiogram (to detect any structural and functional abnormality). (See",
"      <a class=\"local\" href=\"#H24489234\">",
"       'Survivors of SCA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a child or adolescent dies unexpectedly, we suggest an autopsy that includes a full assessment of cardiac anatomy and histology (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If a cardiac anatomic explanation for the SCD episode is not found, a molecular genetic testing should be performed. Further assessment of first-degree relatives is based on the results of family history, autopsy, and genetic testing. (See",
"      <a class=\"local\" href=\"#H24489265\">",
"       'Victims of SCD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because it is unlikely that all episodes of SCA will be prevented, secondary measures that increase the survival of individuals with SCA should be instituted, including increased public access to automated external defibrillators (AEDs) and improving bystander cardiopulmonary resuscitation skills. (See",
"      <a class=\"local\" href=\"#H871783553\">",
"       'Secondary prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/1\">",
"      Van Camp SP, Bloor CM, Mueller FO, et al. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc 1995; 27:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/2\">",
"      Maron BJ, Gohman TE, Aeppli D. Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes. J Am Coll Cardiol 1998; 32:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/3\">",
"      Atkins DL, Everson-Stewart S, Sears GK, et al. Epidemiology and outcomes from out-of-hospital cardiac arrest in children: the Resuscitation Outcomes Consortium Epistry-Cardiac Arrest. Circulation 2009; 119:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/4\">",
"      Harmon KG, Asif IM, Klossner D, Drezner JA. Incidence of sudden cardiac death in national collegiate athletic association athletes. Circulation 2011; 123:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/5\">",
"      Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/6\">",
"      Meyer L, Stubbs B, Fahrenbruch C, et al. Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: a 30-year review. Circulation 2012; 126:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/7\">",
"      Corrado D, Basso C, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden cardiac death? J Cardiovasc Med (Hagerstown) 2006; 7:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/8\">",
"      Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep 2008; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/9\">",
"      Hofman N, Tan HL, Clur SA, et al. Contribution of inherited heart disease to sudden cardiac death in childhood. Pediatrics 2007; 120:e967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/10\">",
"      Tan HL, Hofman N, van Langen IM, et al. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 2005; 112:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/11\">",
"      Section on Cardiology and Cardiac Surgery. Pediatric sudden cardiac arrest. Pediatrics 2012; 129:e1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/12\">",
"      Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med 1996; 334:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/13\">",
"      Drezner JA, Fudge J, Harmon KG, et al. Warning symptoms and family history in children and young adults with sudden cardiac arrest. J Am Board Fam Med 2012; 25:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/14\">",
"      Uberoi A, Stein R, Perez MV, et al. Interpretation of the electrocardiogram of young athletes. Circulation 2011; 124:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/15\">",
"      Fish FA, Kannankeril PJ. Diagnosis and management of sudden death in children. Curr Opin Pediatr 2012; 24:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/16\">",
"      Mahle WT, Sable CA, Matherne PG, et al. Key concepts in the evaluation of screening approaches for heart disease in children and adolescents: a science advisory from the American Heart Association. Circulation 2012; 125:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/17\">",
"      Schoenbaum M, Denchev P, Vitiello B, Kaltman JR. Economic evaluation of strategies to reduce sudden cardiac death in young athletes. Pediatrics 2012; 130:e380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/18\">",
"      Leslie LK, Cohen JT, Newburger JW, et al. Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. Circulation 2012; 125:2621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/19\">",
"      Kaltman JR, Thompson PD, Lantos J, et al. Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. Circulation 2011; 123:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/20\">",
"      Drezner JA, Rao AL, Heistand J, et al. Effectiveness of emergency response planning for sudden cardiac arrest in United States high schools with automated external defibrillators. Circulation 2009; 120:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/21\">",
"      Maron BJ, Thompson PD, Puffer JC, et al. Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. Circulation 1996; 94:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39945/abstract/22\">",
"      Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2007; 115:1643.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Family Physicians, American Academy of Pediatrics, American College of Sports Medicine. Preparticipation Physical Evaluation, 4th ed, Bernhardt D, Roberts W (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2010.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85989 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39945=[""].join("\n");
var outline_f39_0_39945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24489528\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192520686\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192520693\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192520700\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268779676\">",
"      Genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H780323923\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268779936\">",
"      WARNING SIGNS AND SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H780323955\">",
"      Electrocardiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H798045419\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H798045536\">",
"      PREVENTIVE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268780265\">",
"      Primary prevention (screening)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H871783333\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H871783378\">",
"      - Universal versus selective screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H871783385\">",
"      - Age of screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H871783392\">",
"      - Method of screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H871783400\">",
"      - Societal recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H871783553\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060379\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060481\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060510\">",
"      - Newborn",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060556\">",
"      - Routine healthcare visits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060608\">",
"      - Preparticipation sports assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24488717\">",
"      - Further evaluation and referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24489234\">",
"      Survivors of SCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24489265\">",
"      Victims of SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24489289\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24489528\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168191245\">",
"      Epidemiology, etiology, and prodromal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168191266\">",
"      Prevention of SCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/85989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/85989|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?26/24/27008\" title=\"waveform 1\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?34/55/35706\" title=\"waveform 2\">",
"      ECG WPW tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=related_link\">",
"      Approach to chest pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25208?source=related_link\">",
"      Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=related_link\">",
"      Cardiac causes of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36007?source=related_link\">",
"      Causes of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15897?source=related_link\">",
"      Causes of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27204?source=related_link\">",
"      ECG tutorial: Chamber enlargement and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16198?source=related_link\">",
"      ECG tutorial: ST and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23207?source=related_link\">",
"      Idiopathic restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31318?source=related_link\">",
"      Screening to prevent sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/61/19417?source=related_link\">",
"      Short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12409?source=related_link\">",
"      Suspected heart disease in infants and children: Criteria for referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/13/36058?source=related_link\">",
"      The preparticipation sports examination in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_0_39946="Overview of the management of sickle cell disease";
var content_f39_0_39946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Joshua J Field, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Elliott P Vichinsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Michael R DeBaun, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/0/39946/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/0/39946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoocclusive phenomena and hemolysis are the clinical hallmarks of sickle cell disease (SCD). Vasoocclusion results in recurrent painful episodes (previously called sickle cell crisis) and a variety of serious organ system complications that can lead to life-long disabilities and even death. Hemolysis of red blood cells (RBC) causes chronic anemia and pigment gallstones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are multiple components to the management of SCD, including the prevention and treatment of the complications of SCD, as well as the potential cure for this illness:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prevention of complications",
"      </strong>",
"      &mdash; Primary prevention of the acute complications of SCD includes routine health management with a hematologist or a health care provider with expertise in SCD. Initial prevention of complications includes the use of penicillin prophylaxis started in the newborn period, appropriate immunizations, and blood transfusions for those at risk for stroke. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Infection control and prophylaxis'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The only FDA approved therapy to prevent pain episodes in SCD is the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      to reduce sickle hemoglobin polymerization process by increasing the production of fetal hemoglobin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/1\">",
"       1",
"      </a>",
"      ]. This important component of the management of SCD is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"       \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Treatment of complications",
"      </strong>",
"      &mdash; Several treatments are available for the complications of SCD, such as pain medications for vasoocclusive events and antibiotics for infection.",
"     </li>",
"     <li>",
"      <strong>",
"       Cure",
"      </strong>",
"      &mdash; A life-long cure for SCD is available only through a hematopoietic cell transplantation. However, this treatment is primarily limited to individuals under 16 years of age due to the risk of severe toxicities and death among individuals &gt;16 years of age with an HLA-matched sibling transplant. Multicenter trials are now evaluating the safety and efficacy of unrelated HLA-matched transplantation in children, and modified myeloablative programs for adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"       \"Hematopoietic cell transplantation in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will focus on the general principles of management of SCD (eg, treatment of pain and infection and the use of transfusions) and on prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/3\">",
"     3",
"    </a>",
"    ]. Other important management issues are presented separately, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute chest syndrome &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"       \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bone and joint complications &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link\">",
"       \"Bone and joint complications in sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cerebrovascular disease &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Children &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/1/38937?source=see_link\">",
"       \"Routine comprehensive care for children with sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fever &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=see_link\">",
"       \"Management of fever in sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hepatic disease &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2842?source=see_link\">",
"       \"Hepatic manifestations of sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pain management &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=see_link\">",
"       \"Acute pain management in adults with sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pregnancy &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=see_link\">",
"       \"Pregnancy in women with sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prenatal testing &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=see_link\">",
"       \"Prenatal testing for the hemoglobinopathies and thalassemias\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Priapism &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=see_link\">",
"       \"Diagnosis and management of priapism in sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary complications &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link\">",
"       \"Pulmonary complications of sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Renal manifestations &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with SCD should be seen regularly by the clinician and treatment team as part of a comprehensive health care maintenance program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/4\">",
"     4",
"    </a>",
"    ]. Routine office visits are used to educate the affected individual and family about sickle cell disease, pain management strategies, and anticipatory guidance for possible complications (eg, splenic sequestration, avascular necrosis of the femoral head, stroke, leg ulcers). Education regarding the nature of the disease, genetic counseling, and psychosocial assessments of individuals and their families are also best accomplished during these visits, reinforced, when possible, with telephone-based outreach programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, obtaining steady state laboratory values (eg, hemoglobin, reticulocyte count, white blood cell count, pulse oximetry readings) during routine visits will provide standards for comparison during clinical exacerbations, because these values are often abnormal at baseline.",
"   </p>",
"   <p>",
"    A comprehensive health care maintenance program for SCD individuals should include the components discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A National Institutes of Health (NIH) publication, which has not been revised since 2004, outlining a comprehensive health care program for individuals with SCD is available on the NIH website at",
"    <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/prof/blood/sickle\">",
"     www.nhlbi.nih.gov/health/prof/blood/sickle",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Infection control and prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with SCD are highly susceptible to bacterial and viral infections, and their clinical course from these infections is often more severe than individuals without SCD. An overview of possible infections is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunizations are a cornerstone of infection prevention in SCD. Children with SCD should be immunized against Streptococcus pneumoniae, Haemophilus influenzae type B, Neisseria meningitidis, hepatitis B virus, and influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. The response of these individuals to the pneumococcal capsular polysaccharide vaccine is generally poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/11,15\">",
"     11,15",
"    </a>",
"    ], and penicillin prophylaxis does not appear to interfere with an IgG response to re-immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/13\">",
"     13",
"    </a>",
"    ]. For individuals who have received the full complement of 7-valent pneumococcal conjugated vaccine, one vaccination with 13-valent pneumococcal conjugate should be given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/16\">",
"     16",
"    </a>",
"    ]. The 13-valent pneumococcal conjugate vaccine (PCV13) should be given more than one year after the last dose of 23-valent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    . The status of 23-valent pneumococcal polysaccharide vaccine for adults should be noted, and if not given in the last five years, it should be given. The repeat 23-valent pneumococcal polysaccharide should be given at least eight weeks after the PCV13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Annual seasonal influenza vaccination is recommended for all individuals with SCD. When feasible, antibiotic prophylaxis of individuals with SCD who are household contacts of persons with these infections may be indicated.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link\">",
"       \"Prevention of Haemophilus influenzae infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link\">",
"       \"Meningococcal vaccines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"       \"Hepatitis B virus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link\">",
"       \"Seasonal influenza vaccination in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parents of infants and children with SCD should be instructed regarding early recognition of infection. Formal plans should be discussed regarding what strategy will be employed if a child with SCD has developed a fever when traveling or visiting with family members who may not be familiar with the routine. Fever should be considered a",
"    <strong>",
"     medical emergency",
"    </strong>",
"    requiring prompt medical attention and treatment with antibiotics. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Management of infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prophylactic penicillin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic penicillin should be given to all individuals with SCD as 125 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    orally twice daily within three months of birth and continued until two to three years of age. After two or three years, the oral dose should be increased to 250 mg twice daily until the age of five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. After the age of five years, some parents, with consultation of their clinicians, elect to stop penicillin prophylaxis, while others will continue. This is an important issue given the lifelong persistence of splenic dysfunction starting in late childhood and continuing through adulthood. Alternative antibiotic choices for penicillin-allergic individuals are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link&amp;anchor=H11#H11\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of prophylactic penicillin has been demonstrated in two large randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A 2012 Cochrane review of these trials included data from 457 patients with sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/21\">",
"     21",
"    </a>",
"    ]. As compared with no treatment or placebo, penicillin prophylaxis was associated with a decreased risk of pneumococcal infection (odds ratio 0.37; 95% CI 0.16-0.86) and a decreased risk of death (odds ratio 0.11; 95% CI 0.01-2.11). Adverse effects were minimal. Further discussion of these trials and related issues, such as penicillin resistance and country-specific guidelines, is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link&amp;anchor=H11#H11\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial directly evaluated the safety of stopping penicillin prophylaxis in 400 children with SCD who had received penicillin prophylaxis for at least two years immediately before their fifth birthdays and had received the 23-valent pneumococcal vaccine between two and three years of age, and again at the time of randomization (ie, had received optimal prophylaxis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/18\">",
"     18",
"    </a>",
"    ]. The incidence of systemic pneumococcal infection during 3.2 years of follow-up was very low and not significantly different in those receiving placebo or continued penicillin prophylaxis (2 versus 1 percent).",
"   </p>",
"   <p>",
"    Based upon these data, many pediatric clinicians elect to stop prophylaxis if the child has not had a prior severe pneumococcal infection or splenectomy and is receiving comprehensive care. However, others will continue penicillin prophylaxis through adulthood because of the lifelong risk of pneumococcal infection.",
"   </p>",
"   <p>",
"    Regardless of the decision, careful monitoring should be continued because fever is a life-threatening condition among individuals with SCD. Pneumococcal sepsis does occur in children taking penicillin who have received the pneumococcal vaccine, and factors affecting adequacy of pneumococcal prophylaxis should be explored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. As an example, publicly insured children with sickle cell disease often receive inadequate antibiotic prophylaxis. In a review of Washington State and Tennessee Medicaid programs, the average&nbsp;sickle cell disease patient was dispensed&nbsp;only 148 days of prophylactic medication per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/24\">",
"     24",
"    </a>",
"    ]. Efforts to improve penicillin access should therefore be investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30509050\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little prospective data regarding clinical benefit of nutritional interventions that can be used to guide nutritional management in patients with SCD. However, growing evidence suggests that these individuals have vitamin and micronutrient deficiencies that may influence the course of their disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. We therefore use the following in our patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      is given to all individuals in an oral dose of 1 mg daily. Folate deficiency has been found in several observational studies of patients with SCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/28,30-33\">",
"       28,30-33",
"      </a>",
"      ]. Increased folate consumption from ongoing hemolytic anemia is often proposed as a rationale for the use of folic acid in these patients. However, there are no data that folic acid supplementation increases the hematocrit in individuals with SCD; a randomized trial of folic acid supplementation in 117 children with SCD showed that compared with controls, those receiving folic acid did not show an improvement in hemoglobin levels or growth characteristics but did have a decrease in MCV and less dactylitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/31\">",
"       31",
"      </a>",
"      ]. Despite this, we believe that the potential yet unknown benefit from folic acid supplementation outweighs the potential harms.",
"     </li>",
"     <li>",
"      We use a daily multivitamin",
"      <strong>",
"       without",
"      </strong>",
"      iron for all of our patients. This replaces some of the vitamins and micronutrients commonly reported to be deficient in these individuals, including zinc, vitamin D, vitamin E, vitamin C, vitamin A, magnesium,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      , carotenoids, and flavonoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]. Iron overload and oxidative injury may contribute to the depletion of antioxidant vitamins.",
"     </li>",
"     <li>",
"      For individuals found to be vitamin D deficient, additional supplementation with oral vitamin D and calcium is appropriate. Vitamin D deficiency is under-recognized and undertreated in the SCD population; observational studies have demonstrated that a majority of children with SCD are vitamin D deficient and have inadequate calcium intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. These deficiencies may contribute to osteopenia and osteoporosis, which affect up to 80 percent of patients with SCD. There is also an incompletely understood relationship between vitamin D deficiency and chronic pain in children with SCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Routine evaluations and treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine evaluations and associated treatments of individuals with sickle cell disease are extensive, and include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure screening should be done at every visit. Early treatment of systemic hypertension is critical because mild elevations in blood pressure are associated with an increased risk of overt stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/37\">",
"       37",
"      </a>",
"      ] and silent cerebral infarct [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/38\">",
"       38",
"      </a>",
"      ] in individuals with SCD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link\">",
"       \"Overview of hypertension in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children &le;16 years of age with hemoglobin SS or hemoglobin S beta thalassemia that produces no hemoglobin A, referred to as S beta thalassemia zero, cerebral blood flow should be evaluated by transcranial Doppler (TCD) annually, because children at risk for cerebrovascular accidents can be identified with this technique and the incidence of stroke can be reduced by the use of regular blood transfusion therapy aimed at maintaining the maximum hemoglobin S level at less than 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/39\">",
"       39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Optimal intervals for TCD measurements have not been formally evaluated, but TCD measurements should be started at two years of age and performed at least every 12 to 24 months. Serial TCD screening is recommended because normal flow velocity on a single screening does not assure a continued low risk status. This issue is discussed in detail elsewhere. TCD measurements are lower in adults with SCD compared with children, and there is no evidence to suggest that TCD velocities are predictive of stroke risk in adults. We do not recommend TCD screening in individuals &gt;16 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H8#H8\">",
"       \"Cerebrovascular complications of sickle cell disease\", section on 'Prevention of a first stroke'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retinal evaluation is begun at 10 years of age and continued routinely to detect early proliferative sickle retinopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H40#H40\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Proliferative sickle retinopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening echocardiogram with a brain natriuretic peptide (BNP) should be done at least every two years in patients &gt;21 years of age. If an elevated tricuspid regurgitant jet velocity is greater than 2.5",
"      <span class=\"nowrap\">",
"       cm/second",
"      </span>",
"      or the BNP is elevated, further evaluation, such as with the six-minute walk and potentially a right heart catheterization, is warranted. Before 21 years of age, we perform an echocardiogram along with a BNP and six-minute walk in individuals with symptoms such as shortness of breath with minimum exertion, decreased oxygen saturation, or evidence of progressive restrictive lung disease.",
"     </li>",
"     <li>",
"      Baseline pulmonary evaluation that includes at least assessment of severe recurrent wheezing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/42\">",
"       42",
"      </a>",
"      ], shortness of breath with exercise, or persistent cough should be done as part of routine review of systems with ongoing health maintenance visits. In the event of a positive history, especially in those with a history of pulmonary disease, pulmonary function test including lung volumes should be considered annually. For individuals with abnormal spirometry results, spirometry and lung volumes should be done. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link\">",
"       \"Pulmonary complications of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Interview concerning history of priapism, which is usually not volunteered because of the sensitivity of the issue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=see_link\">",
"       \"Diagnosis and management of priapism in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bi-annual chemistry panel and urinalysis is done to monitor renal disease, proteinuria, and organ dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment about family planning and birth control needs, with ongoing discussion of options. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=see_link\">",
"       \"Prenatal testing for the hemoglobinopathies and thalassemias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=see_link\">",
"       \"Pregnancy in women with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of psychological well-being; depression is a serious component of chronic disease. At least annual screening for depression and, when appropriate, therapy should be considered, along with an annual screening for neurocognitive deficits that may impair decision making and complex problem solving. In high risk individuals, such as those with major school difficulties or signs of neurocognitive dysfunction, detailed neurocognitive testing is advised. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Medical comorbidity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation for leg ulcers and education concerning their prevention are important, particularly in areas with warm climates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H31#H31\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Leg ulcers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of bone health by calcium intake, vitamin D status, and bone density at 12 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/34\">",
"       34",
"      </a>",
"      ], and screening physical exam for avascular necrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link\">",
"       \"Bone and joint complications in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These routine evaluations and treatments should be tailored for individual patients when co-morbidities are present (eg, chronic renal insufficiency, interstitial lung disease). This is especially true for adults with SCD, as end-organ dysfunction is prevalent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    is a mainstay in the overall management of individuals with SCD, since it reduces the incidence of acute painful episodes and hospitalization rates, and prolongs survival. This important subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SPLENIC SEQUESTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic sequestration in SCD is characterized by the following four features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Splenic enlargement, often tender",
"     </li>",
"     <li>",
"      A drop in hemoglobin concentration of at least 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Reticulocytosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Splenic sequestration is commonly observed in infants as young as two months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/44\">",
"     44",
"    </a>",
"    ]; however, the same event may occur in adolescents and adults may also have an acute splenic sequestration episode, particularly those with SCD-SC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Splenic sequestration crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary concern in the event of a splenic sequestration episode is hypovolemic shock resulting from a disproportionate amount of the intravascular blood volume being sequestered in the spleen because of ensnared red and white blood cells. Hence, management should be directed at maintaining the individual in a euvolemic state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of an acute splenic sequestration episode in adults is based on the following principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high index of suspicion when an individual presents with a sudden drop in hemoglobin, thrombocytopenia, reticulocytosis, and an enlarged spleen.",
"     </li>",
"     <li>",
"      Assessment of volume status, with the goal of maintaining the individual in a euvolemic state that may require administration of isotonic solution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the individual is hypovolemic and is symptomatic from anemia, a simple blood transfusion therapy should be considered. However, caution should be used when transfusing the individual, as the blood trapped in the spleen is still available to",
"    <strong>",
"     re-enter",
"    </strong>",
"    the circulation. Accordingly, following such transfusion the individual's hemoglobin may rise acutely to levels that result in hyperviscosity syndrome.",
"   </p>",
"   <p>",
"    To decrease the likelihood of hyperviscosity syndrome occurring after a simple blood transfusion, we typically transfuse the individual with approximately 50 percent of what we would commonly transfuse. Thus, instead of transfusing the adult individual with two units of blood, we transfuse a single unit of blood or calculate (and deliver) the amount of blood needed to get the individual back to",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    baseline level and re-evaluate the clinical status after transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of splenic sequestration in infants and toddlers with SCD is well documented, with a reasonable proportion having a second event within 12 months of the first event. However, in adults with SCD, limited data exist to describe the risk of subsequent splenic sequestration episodes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Future management should include education about self-palpation of the spleen and instructions on what to do in the event of an enlarging spleen.",
"     </li>",
"     <li>",
"      After consideration of risks and benefits, there should be a discussion of the potential removal of the spleen in a non-acute setting.",
"     </li>",
"     <li>",
"      Institution of regular blood transfusion therapy to prevent subsequent episodes of acute splenic episodes is not indicated and has not proven to be of benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of acute pain episodes in individuals with SCD is discussed separately. A number of important general statements about this issue are discussed below. Importantly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended for the treatment of painful episodes of SCD, because multiple doses are associated with accumulation of normeperidine and central toxicity, including but not limited to mild twitching, multifocal clonus, and seizures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=see_link\">",
"     \"Acute pain management in adults with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H458917\">",
"    <span class=\"h2\">",
"     Acute pain episode",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute painful episode is the most frequent cause for individuals with SCD to seek medical attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/47\">",
"     47",
"    </a>",
"    ]. The approach to such individuals consists of exclusion of causes other than vasoocclusion (particularly infection), optimal hydration by oral or intravenous fluid resuscitation (especially in children), and aggressive pain relief using opiates, other analgesics, or other modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=see_link\">",
"     \"Acute pain management in adults with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood transfusion in a patient with acute vaso-occlusive pain episodes is indicated when the patient is hemodynamically unstable. However, blood transfusion is not indicated to abate the acute pain episode, as there is no established benefit for transfusion therapy in the setting of an uncomplicated pain episode and with no evidence of symptomatic anemia. Simple blood transfusion during an acute pain episode without evidence of hemodynamic instability places the patient at risk for complications of a blood transfusion without any short term clinical benefit.",
"   </p>",
"   <p>",
"    Individuals are often undertreated for pain because many clinicians are unfamiliar with the pharmacology of analgesia and overly concerned with the potential for addiction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Possible contributors to suboptimal therapy include genetic differences in the rate at which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    is metabolized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/52\">",
"     52",
"    </a>",
"    ], and ethnic, racial, and socio-cultural biases in the prescribing of opioids for African-Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/53-57\">",
"     53-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, the duration of painful episodes may be prolonged, a \"drug-seeking\" (ie, pain-relieving) behavior pattern is encouraged, and a pain-oriented personality may evolve. Individuals with SCD do not appear to be more likely than others to develop an addiction to these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/9,51\">",
"     9,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals in pain are best treated in a familiar, ambulatory day care setting that avoids the hectic environment of an emergency department (ED); avoidance of the ED is particularly important in off hours, when the individual may wait long periods of time before pain control is initiated and appropriate repeat dosing is given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Day care settings for individuals with SCD are populated by staff more familiar with analgesic agents and opiates, and can deliver adequate degrees of pain relief without inordinate delay, using doses specifically tailored to needs of the specific individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some individuals, sickle cell pain is a chronic syndrome. Chronic pain can be due to a specific injury, such as leg ulcers and avascular necrosis. These should be treated with specific therapy. Chronic pain without overt pathology requires a multi-disciplinary team. Compound causes, such as neuropathic pain and hyperanalgesia syndrome, should be investigated.",
"   </p>",
"   <p>",
"    The prevalence of chronic pain in SCD was established in a prospective cohort study of adults who maintained a pain diary for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/62\">",
"     62",
"    </a>",
"    ]. In 232 adults with SCD (mean age 33 years), 29 percent reported pain on &gt;95 percent of days. Utilization of hospital, emergency department or ambulatory care for management of pain only occurred on 3.5 percent of days. These data demonstrate that chronic pain occurs in a significant subset of adults with SCD and is largely managed at home.",
"   </p>",
"   <p>",
"    For patients with sickle cell disease and chronic pain, the pain differs from other forms of chronic pain (eg, cancer pain) in that sickle cell pain is typically associated with episodic and chaotic waxing and waning acute pain on top of chronic pain. There is also likely to be a larger component of neuropathic pain and hyperalgesia in patients with SCD. In addition, unlike individuals with cancer who have pain, patients with SCD live with this pain for decades. Nevertheless, the management of chronic pain in SCD uses agents similar to those used for the pain of advanced cancer. These include long-acting oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , and transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/63\">",
"     63",
"    </a>",
"    ]. Methadone, in particular, may have advantages over other opioids for the management of chronic pain in SCD due to mechanisms of N-methyl-D-aspartate (NMDA) antagonism and monoamine uptake inhibition, in addition to opioid agonism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/64\">",
"     64",
"    </a>",
"    ]. For patients with a neuropathic component to their pain, methadone may be efficacious due to NMDA antagonism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link&amp;anchor=H21149184#H21149184\">",
"     \"Overview of the treatment of chronic pain\", section on 'Methadone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is a frequent complication of SCD and is particularly serious when accompanied by bacteremia. Management of the febrile child with SCD begins with the following evaluation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of fever in sickle cell disease\", section on 'Acute management'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Blood and urine cultures",
"     </li>",
"     <li>",
"      Lumbar puncture if meningitis is suspected",
"     </li>",
"     <li>",
"      Chest x-ray",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of the complete blood count are compared with baseline values. A \"left shift\" (ie, the presence of increased band forms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metamyelocytes in the white blood cell differential count) suggests bacterial infection. In the past, due to the high mortality rate of bacteremia, children with temperatures higher than 38.5&deg;C were hospitalized routinely and given parenteral antibiotics after blood and cerebrospinal fluid cultures were obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. However, the proven efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    has allowed outpatient management of individuals with a low risk of sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/69-72\">",
"     69-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Febrile episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Febrile episodes without localized symptoms are treated according to the estimated risk. We recommend use of the following guidelines for the management of the febrile child with SCD who has negative chest x-rays and initial evaluations for serious infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       High risk",
"      </strong>",
"      &mdash; Individuals with sickle cell anemia or sickle cell-beta(0) thalassemia who appear toxic, have temperatures &gt;40&deg;C, or are non-adherent with follow-up, are considered high risk and should be hospitalized for administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously). A rare complication of intravenous ceftriaxone therapy in individuals with SCD is an immune-mediated hemolytic anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/73,74\">",
"       73,74",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      <strong>",
"       Low risk",
"      </strong>",
"      &mdash; Low risk individuals include those with sickle cell anemia or sickle cell-beta(0) thalassemia with temperatures &lt;40&deg;C who are compliant with prophylactic penicillin and those with HbSC disease or sickle cell-beta(+) thalassemia who have temperatures &gt;38.5&deg;C. The recommended approach for these individuals is to obtain blood cultures, administer ceftriaxone (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously or 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intramuscularly up to a maximum dose of 2 g), and observe for several hours in the emergency department, with close outpatient follow-up.",
"      <br/>",
"      <br/>",
"      Whether the patient is in the high or low risk category, the immunization status, particularly the conjugated Streptococcus pneumonia vaccine and the conjugated Haemophilus influenzae type B vaccine, should be documented because patients without such vaccinations are at increased rate of infection. The current low rate of sepsis and infectious complications is most likely attributable to childhood immunization schedules with these two conjugated vaccines several decades ago; however, immigrant populations or other select groups may not have been immunized, and outpatient management of fever may have to be adjusted accordingly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with HbSC disease or sickle cell-beta(+) thalassemia with temperatures &lt;38.5&deg;C are treated symptomatically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Specific infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of specific infections varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteremia &mdash; Several days of parenteral penicillin or cephalosporin therapy followed by oral antibiotics is appropriate therapy for documented S. pneumoniae bacteremia. Due to the emerging evidence that multiple doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      are associated with life-threatening hemolytic episodes, we use alternative cephalosporins in children and adults with SCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/73-75\">",
"       73-75",
"      </a>",
"      ] or a single dose of ceftriaxone.",
"     </li>",
"     <li>",
"      Meningitis &mdash; Therapy for meningitis should provide coverage for S. pneumoniae and H. influenzae type b and should be continued for at least two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/76\">",
"       76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=see_link\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute chest syndrome &mdash; Antibiotics should provide coverage for S. pneumoniae, H. influenzae type b, Mycoplasma pneumoniae, and Chlamydia pneumoniae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/77\">",
"       77",
"      </a>",
"      ]. We recommend the combination of a third generation cephalosporin and a macrolide, unless there is an appreciable incidence of high-grade penicillin-resistant pneumococcal infection in the area. These isolates may also be resistant to cephalosporins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link&amp;anchor=H3#H3\">",
"       \"Pulmonary complications of sickle cell disease\", section on 'Acute chest syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"       \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19704?source=see_link\">",
"       \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/81?source=see_link\">",
"       \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9066?source=see_link\">",
"       \"Acute chest syndrome in adults with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteomyelitis &mdash; The diagnosis of osteomyelitis should be confirmed by culture of blood or infected bone. This infection should be treated with parenteral antibiotics that cover Salmonella and Staphylococcus aureus until culture results are available. Parenteral antibiotics are continued for two to six weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/78\">",
"       78",
"      </a>",
"      ]. Surgical drainage or sequestrectomy may be required. Most individuals are cured with this approach, but there may be recurrences. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=see_link\">",
"       \"Overview of osteomyelitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link&amp;anchor=H12#H12\">",
"       \"Bone and joint complications in sickle cell disease\", section on 'Osteomyelitis and septic arthritis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TRANSFUSION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic transfusion with red blood cells lowers the percent of sickle hemoglobin (HbS) in subjects with sickle cell disease by three mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dilution of HbS via the addition of HbA from the blood of normal donors",
"     </li>",
"     <li>",
"      Suppression of erythropoietin release secondary to the rise in hematocrit, thereby reducing the production of new erythrocytes containing HbS",
"     </li>",
"     <li>",
"      Decreased levels of HbS due to the longer circulating lifespan of HbA-containing normal erythrocytes compared with sickle erythrocytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transfusion therapy for individuals with SCD can be categorized as therapeutic or prophylactic. Accepted indications for transfusion therapy in individuals with SCD include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Therapeutic",
"      </strong>",
"      &mdash; Acute use of transfusions for acute stroke, acute chest syndrome, acute multi-organ failure, acute symptomatic anemia (eg, onset of heart failure, dyspnea, hypotension, marked fatigue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/9\">",
"       9",
"      </a>",
"      ]), reticulocytopenia (most commonly associated with Parvovirus B19 infection, but can occur with any infection), or following hepatic or splenic sequestration.",
"     </li>",
"     <li>",
"      <strong>",
"       Prophylactic",
"      </strong>",
"      &mdash; Use of periodic red cell transfusions for primary or secondary stroke prevention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of interest, in the Stroke Prevention Trial (STOP), which randomly assigned children with SCD and abnormal transcranial Doppler ultrasonography to receive chronic transfusion or observation, transfusion not only reduced the risk of stroke, but also significantly reduced rates of hospitalization for acute chest syndrome and pain episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/83\">",
"     83",
"    </a>",
"    ]. In addition, subjects with SCD who received chronic transfusions for two years had improved growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H8#H8\">",
"     \"Cerebrovascular complications of sickle cell disease\", section on 'Prevention of a first stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transfusion therapy to prevent pain or acute chest syndrome episodes in severely affected individuals with SCD is an option for selected patients. The potential benefit of transfusion therapy must be weighed against potential risks, including transfusion reactions, viral infection, iron overload, and alloimmunization. There is no established benefit for transfusion therapy in the setting of an uncomplicated pain episode without symptomatic anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Transfusion techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with SCD, simple transfusion of red cells is used to acutely restore oxygen carrying capacity or blood volume, while partial exchange transfusions are recommended when the desired endpoint is an acute or chronic reduction in the concentration of sickle hemoglobin (eg, for acute emergencies such as multi-organ failure, suspected stroke, respiratory compromise, including acute chest syndrome; primary and secondary prevention of stroke; and prevention of recurrent painful episodes) as well as for the lessened effects on viscosity and iron burden following partial exchange transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/79,85,86\">",
"     79,85,86",
"    </a>",
"    ]. In general, automated pheresis is a better technique than manual exchange transfusion, and should be utilized whenever available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Transfusion volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volumes required for simple and exchange transfusions can be estimated and are particularly important for transfusing children. The indications for transfusion are listed in the discussions of the individual manifestations of SCD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The general rule for normal size adults is that each unit of red cells infused will increase the hemoglobin concentration by approximately 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or 3 percentage points in the hematocrit. Partial exchange transfusion in adults is accomplished by phlebotomizing 500 mL, infusing 300 mL normal saline, phlebotomizing another 500 mL, and infusing 4 to 5 units of packed red cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/87,88\">",
"       87,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children, the following formulae are used for estimation of simple transfusion and partial exchange transfusion volumes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/89\">",
"       89",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Packed red cell volume for simple transfusion (mL) =",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; ([dHCT - iHCT] &nbsp;x &nbsp;TBV) &divide; rpHCT",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Manual partial exchange volume (mL) =",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; ([dHCT - iHCT] &nbsp;x &nbsp;TBV) &divide; (rpHCT &nbsp;- &nbsp;[(iHCT + dHCT) &divide; 2])",
"   </p>",
"   <p>",
"    Where dHCT is the desired hematocrit, iHCT is the initial hematocrit (both given as percent, eg, 40 percent), TBV is the estimated total blood volume in mL (80",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    in children), and rpHCT is the hematocrit of the replacement packed red cells (usually 75 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the technique employed, hyperviscosity syndrome from over-transfusion should be avoided. Viscosity is determined by an interrelationship between total hemoglobin, percent hemoglobin S, and flow rates, white blood cell count and other parameters. In patients with high hemoglobin S levels, the hemoglobin concentration should not be raised much above 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    because of increases in viscosity and the risk of vasoocclusive episodes. When the hemoglobin S concentration is high (&gt;50 percent), patients should generally not be transfused to hemoglobin levels above 12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Additionally, exchange blood transfusion via red blood cell pheresis techniques or manual exchange may be more beneficial than simple transfusion therapy when there is rapid compromise of an organ, such as a suspected stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/90\">",
"     90",
"    </a>",
"    ], respiratory failure, or multi-organ failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the most conservative use of transfusions, approximately 70 to 80 percent of individuals with SCD receive at least one transfusion by the age of 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prophylactic preoperative transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with SCD have a high frequency of serious perioperative complications. This observation led to some controversy surrounding the optimal regimen of prophylactic preoperative transfusion. This issue has largely been resolved by the results of multicenter cooperative studies performed by the National Preoperative Transfusion in Sickle Cell Disease Study Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/93-97\">",
"     93-97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one such study, individuals undergoing 604 operations were randomly assigned to receive either an aggressive exchange transfusion regimen designed to reduce the HbS level to &lt;30 percent or a conservative transfusion regimen designed only to increase the hemoglobin concentration to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/93\">",
"     93",
"    </a>",
"    ]. The incidence of serious complications (31 and 35 percent) and acute chest syndrome (10 percent) were not different in the two groups, although the aggressive transfusion group had a higher rate of transfusion-related complications (14 versus 7 percent).",
"   </p>",
"   <p>",
"    Other studies have confirmed the equivalent outcomes in the two groups, although the serious complication rate varied with the type of surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orthopedic surgery &mdash; 67 percent serious surgical complications and 17 percent sickle-related complications (acute chest syndrome and vasoocclusive crises) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cholecystectomy &mdash; 39 percent serious complications, 19 percent sickle-related complications, and 10 percent transfusion-related complications. Subjects who were not transfused in this study appeared to have a higher incidence of sickle-related complications (32 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ear, nose, and throat surgery &mdash; 32 percent serious complications with tonsillectomy and adenoidectomy and 36 percent for myringotomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Hemoglobin SC disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar principles apply to individuals with combined heterozygosity for both HbS and HbC (ie, HbSC disease, SCD-SC). In keeping with the less severe nature of this condition, affected individuals have lower rates of overall complications (18 percent) and sickle-related complications (9 percent) than those with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/98\">",
"     98",
"    </a>",
"    ]. In uncontrolled observations, sickle-related complications occurred only in individuals who were not transfused (35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/98\">",
"     98",
"    </a>",
"    ]. However, the value of transfusion in such individuals remains to be proven. Since hemoglobin levels in some individuals with SCD-SC may be &gt;10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    partial exchange transfusion may be preferable to simple transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell transfusion complications include immunologic reactions: alloimmunization, auto-antibody formation, hemolytic transfusion reactions, and Coombs-negative hemolysis. Infection complications are uncommon but include sepsis from line or unit contamination, and transmission of viral illness such as hepatitis and HIV. In the United States, transmission of serious viral infections is very rare except for parvovirus. Excessive accumulation of iron is a serious problem and may be undetected because transfusion therapy may be irregular and episodic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Alloimmunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of minor red blood cell antigen matching, alloimmunization occurs in approximately 30 percent of transfused individuals with SCD; this is much higher than the 5 percent rate in individuals with other forms of anemia, a difference primarily due to minor blood group incompatibilities between the donor population, which is predominantly white, and the recipient SCD population, which is predominantly of African descent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. Antibodies against the Rh (E, C), Kell (K), Duffy (Fya, Fyb), and Kidd (Jk) antigens present the greatest problem in transfusing these individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/99,100,102\">",
"     99,100,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27480?source=see_link&amp;anchor=H9#H9\">",
"     \"The incompatible crossmatch\", section on 'Sickle cell disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendations from sickle cell centers and expert panels include the utilization of leukoreduced, phenotypically-matched units including at least C, E, and Kell. Alloimmunization can be minimized by transfusing blood matched at minor RBC antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/99,103-109\">",
"     99,103-109",
"    </a>",
"    ]. As examples of the success of this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 61 individuals who received a total of 1830 units of leukoreduced red cells, which were matched for C, E, and Kell antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/110\">",
"       110",
"      </a>",
"      ] demonstrated a marked decrease in alloimmunization and transfusion reactions. The alloimmunization rate dropped from 30 to 5 per 1000 units transfused, and hemolytic transfusion reactions dropped by 90 percent.",
"     </li>",
"     <li>",
"      A retrospective study evaluated the risk of alloimmunization for 99 patients with SCD who were transfused with 6946 red cell units using an extended matching protocol in which patients and donors were phenotyped for 20 blood group antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/111\">",
"       111",
"      </a>",
"      ]. Red cell units that were negative for antigens not expressed by the recipient were provided. During the period of study (1993 through 2006) seven alloantibodies were detected in seven patients, for a rate of one antibody per 1000 units transfused.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While data for extended red cell phenotyping are encouraging, long term randomized trials are lacking. However, blood bank programs that have minority recruitment programs have improved access to matched units and are cost effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/101,112,113\">",
"     101,112,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the growing literature in support of phenotypically-matched blood for individuals with SCD, transfusion practices are not uniform and are largely determined by the type of institutional services for sickle cell disease. Over 75 percent of sickle cell centers, as well as the majority of academic medical centers, recommend phenotypically-matched units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/107\">",
"     107",
"    </a>",
"    ]. However, only 37 percent of blood banks in general community hospitals use phenotypically-matched units in non-alloimmunized patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/114\">",
"     114",
"    </a>",
"    ]. These policies are changing as new technology and data become available. Increasing numbers of programs are utilizing DNA analysis for red cell antigens. This technique determines polymorphisms associated with antigen expression for common blood group systems, and allows the ability to identify better phenotype-compatible donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/114,115\">",
"     114,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158337\">",
"    <span class=\"h3\">",
"     Transmission of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion transmission of HIV, hepatitis B and C, and HTLV-I has diminished markedly with improved screening of banked units (",
"    <a class=\"graphic graphic_table graphicRef69661 \" href=\"mobipreview.htm?30/59/31676\">",
"     table 1",
"    </a>",
"    ). These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    .) Individuals with SCD who have immigrated to the United States may have previously received contaminated units and should be screened for viral hepatitis and HIV. Transfused sickle cell patients may be at particular risk for emerging transfusion-associated infections including babesiosis and malaria. Screening for both organisms is not presently done. A high degree of suspicion is needed for early detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/116,117\">",
"     116,117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that the presence of cytomegalovirus (CMV) antibody is a nonspecific assay for CMV infectivity, and that 30 to 70 percent of blood donors, depending upon geographic region, test positive for the presence of CMV antibody, much effort has gone into finding another method of providing \"CMV-safe\" blood. Blood depleted of leukocytes below a level of five million per unit of blood is an acceptable alternative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link&amp;anchor=H11#H11\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Viral diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Excessive iron stores",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158060\">",
"    <span class=\"h3\">",
"     Complications and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of excessive iron stores was not thought to be an important issue in the past because of the short lifespan of individuals with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/87\">",
"     87",
"    </a>",
"    ]. However, the subsequent increase in longevity (median age at death of about 45 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/118\">",
"     118",
"    </a>",
"    ]), and the frequent use of transfusion therapy, whether episodic or chronic, has resulted in clinically important hemosiderosis in many individuals with SCD. Transfused sickle cell patients have evidence of hepatic fibrosis, and death from hemosiderosis-related cirrhosis of the liver has been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/119-122\">",
"     119-122",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Prognosis'",
"    </a>",
"    below.) Hepatitis therapy has improved and is warranted and should be considered in sickle cell patients who have active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/123\">",
"     123",
"    </a>",
"    ]. Liver transplantation is a high risk but potentially effective option for selected patients with liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/124,125\">",
"     124,125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In multi-transfused individuals with sickle cell disease, liver disease is common, with cirrhosis in almost half the patients who died with liver hemosiderosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/126\">",
"     126",
"    </a>",
"    ]. In adults, one study reported that mortality and morbidity was higher in iron-overloaded individuals with sickle cell compared with those who did not have hemosiderosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/127\">",
"     127",
"    </a>",
"    ]. While lower rates of endocrine complications and excessive cardiac iron have been seen in sickle cell disease compared with thalassemia major, such complications have still been noted in individuals with sickle cell disease. The mechanism for this difference is unknown and may reflect lower transfusion rates, inflammation, and higher plasma hepcidin values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/126\">",
"     126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum ferritin concentration is a useful test to monitor the status of iron stores, particularly in the first few years of blood transfusion therapy. Ferritin levels need to be serially measured at least every three to four months, and must be drawn in the steady state separate from acute inflammatory events or vaso-occlusive crises. We prefer to draw the ferritin levels with each blood draw so that we can easily monitor the trend within an individual, which is probably more important than a single measure. When a definitive measure of iron stores is required for clinical management decision, the ferritin level does not replace the benefit of non-invasive quantitative MRI measurement of iron stores. Based on expert opinion, maintaining a serum ferritin level below 2500",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    has been demonstrated to decrease cardiac disease and death in patients with excessive iron stores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/126,128\">",
"     126,128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multidisciplinary team that includes at least a medical social worker and a nurse case manager approach is optimal and should include staff familiar with the toxicity and compliance issues associated with iron chelation and prevention of organ injury. Annual assessments in centers that have access to non-invasive, quantitative liver and cardiac MRI iron measurements are recommended. These techniques rely on the fact that iron exerts a magnetic effect on surrounding tissues, altering the relaxation time of molecules excited by the application of a magnetic field. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'CT, MRI, and SQUID techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158200\">",
"    <span class=\"h3\">",
"     Chelation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phlebotomy cannot be used to remove iron in transfusion-dependent subjects and is useful only in the rare individual with sickle cell disease and a high hematocrit. In such cases, automated pheresis is effective in decreasing the iron burden and may prevent the need for chelation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/82,129,130\">",
"     82,129,130",
"    </a>",
"    ], which is otherwise necessary to treat and prevent complications of iron overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/131\">",
"     131",
"    </a>",
"    ]. Chelation therapy and monitoring recommendations for individuals with SCD are similar to those for other chronically transfused, iron-overloaded individuals (eg, beta thalassemia major). This subject is discussed in depth separately, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three available iron chelators exist:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    . Deferoxamine is effective, FDA-approved, and available, but requires daily subcutaneous infusions, which often result in poor compliance. Deferiprone was approved in 2011 for use in the United States and has been utilized worldwide for many years. Its major side effect is the risk of agranulocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"     Deferasirox",
"    </a>",
"    is an orally-available iron chelator that appears to have efficacy similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    in decreasing liver iron concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. The side effect profile of deferasirox appears to be tolerable in individuals with SCD. Diarrhea, nausea and vomiting, and abdominal pain are common side effects of deferasirox, but are usually mild and decrease with time. In multicenter trials, laboratory abnormalities include dose-dependent rise in serum creatinine, which is reversible, and occasional liver dysfunction. Long term follow-up studies of five years have shown a clinically acceptable safety profile with no evidence of progressive or irreversible renal or liver injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-marketing surveillance in subjects taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    has identified hepatic failure as a complication in high risk individuals, such as patients with pre-existing liver failure and hepatitis C. Accordingly, serum transaminases and bilirubin should be monitored twice during the first month after initiation of therapy with deferasirox, and monthly afterward. The safety and efficacy of combining deferasirox and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    for severely affected individuals appears promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The correct dose of chelation therapy is determined by the patient&rsquo;s iron stores, transfusion rate, and the presence of organ dysfunction. In general, in stable patients without iron-induced cardiac dysfunction, the starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    is 30 to 40",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    eight hours per day, five days per week, or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    at 20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    once daily. Most patients require modification of dosing based upon response and organ function over time.",
"   </p>",
"   <p>",
"    The initiation of chelation therapy in sickle cell disease is dependent on the number of transfusions given, the degree of iron deposition in the liver and heart, the amount of hepatic and cardiac dysfunction present, and the type of transfusion regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/126,128\">",
"     126,128",
"    </a>",
"    ]. Generally, in chronically-transfused individuals, chelation therapy is started after two years of transfusion, or approximately 200 mL of transfused red cells per kilogram, and when the ferritin exceeds at least 1000 to 1500",
"    <span class=\"nowrap\">",
"     g/L,",
"    </span>",
"    or the liver iron is &gt;7",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    dry weight. A quality-of-care indicator from the American Academy of Pediatrics suggests that such children receive chelation therapy to maintain a ferritin &lt;1500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or liver iron &lt;7",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    dry weight either by liver biopsy or MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many individuals with sickle cell disease are only episodically or intermittently transfused, but may also require chelation therapy. Their chelation therapy should follow similar initiation guidelines, but the schedule of chelation therapy may be different. While long-term efficacy and safety studies on the effects of chelation on morbidity and mortality have not been completed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/137\">",
"     137",
"    </a>",
"    ], existing data and multiple consensus reports recommend iron chelation therapy for transfusion iron overload in sickle cell disease and other syndromes such as thalassemia, Blackfan-Diamond, aplastic anemia, and myelodysplastic syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     GRANULOCYTE COLONY-STIMULATING FACTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three case reports have indicated that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) in individuals with sickle cell syndromes (eg, SCD-SS, SCD-SC, and SCD-beta(+) thalassemia) has been associated with sickle cell crisis and multiorgan failure; at least one individual has died as a result of this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/138-140\">",
"     138-140",
"    </a>",
"    ]. G-CSF may also play a role in the acute chest syndrome and the complications associated with it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/142\">",
"     142",
"    </a>",
"    ] have therefore concluded that G-CSF administration is",
"    <strong>",
"     absolutely contraindicated",
"    </strong>",
"    in individuals with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/143\">",
"     143",
"    </a>",
"    ]. This agent has, however, been shown to be safe in individuals with sickle cell trait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvements in the management of SCD have led to a prolongation of life expectancy well above the mean survival of 14.3 years that was noted in 1973 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/118,145-147\">",
"     118,145-147",
"    </a>",
"    ]. This was illustrated in a study published in 1994 in which 3764 individuals were followed in an attempt to determine current life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/118\">",
"     118",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The median age at death for individuals with SCD was 42 years for men and 48 years for women.",
"     </li>",
"     <li>",
"      The median age at death for individuals with HbSC disease was 60 years for men and 68 years for women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar study, reported in 2001 and based on 3301 individuals attending a sickle cell clinic in Jamaica, estimated a median survival of 53 and 58 years for men and women with homozygous SCD, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among adults with SCD, 18 percent of the deaths occurred in individuals with overt organ failure, predominantly renal, and 33 percent of deaths occurred during an acute sickle cell crisis in the absence of organ failure. A high level of HbF predicted improved survival and was a helpful childhood forecaster of adult life expectancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prediction of adverse outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, the risks of more specific therapies, such as the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    or hematopoietic cell transplantation (HCT), should be commensurate with the risks of untreated SCD. Potentially curative treatments such as HCT should ideally be initiated before there is irreversible organ damage. Attainment of this goal requires the ability to distinguish individuals at high risk as early as possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link\">",
"     \"Specific therapies for sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective study analyzed the records of 392 infants with SCD or sickle cell-beta thalassemia to correlate subsequent clinical outcome with manifestations appearing in the first two years of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/148\">",
"     148",
"    </a>",
"    ]. With data available for approximately 10 years, adverse outcomes, defined as death, stroke, frequent pain, or recurrent chest syndrome occurred in 70 individuals (18 percent). Three variables appearing in the first two years of life were significantly associated with an adverse clinical course:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early dactylitis (ie, pain and tenderness in the hands or feet occurring before the age of one year) &mdash; relative risk (RR) 2.55; 95% CI 1.39-4.67",
"     </li>",
"     <li>",
"      Hemoglobin concentration &lt;7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      &mdash; RR 2.47; 95% CI 1.14-5.33",
"     </li>",
"     <li>",
"      Leukocytosis in the absence of infection &mdash; RR 1.80; 95% CI 1.05-3.09",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, results from this study were not replicated in a later cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/149\">",
"     149",
"    </a>",
"    ] and are not applicable to the current era of management of sickle cell disease for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cohort was assembled during the time that prophylactic penicillin and conjugated pneumococcal and haemophilus influenza type B vaccine were not used routinely. Thus, many of the infection-related deaths in the cohort are preventable today. An update on current prognosis of children with SCD can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Survival and prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      greatly attenuates the rate of many SCD complications, such as pain episodes and acute chest syndrome, both of which are associated with death.",
"     </li>",
"     <li>",
"      General care for individuals with SCD has improved since the cohort was assembled (ie, late 1970s until 1998), including but not limited to the routine use of transcranial Doppler and regular blood transfusion therapy for the primary prevention of stroke, as this is also a major contributor to death in this population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An attempt to identify risk factors was also made in a life expectancy study of 3764 individuals (age range: 2 to 66 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/118\">",
"     118",
"    </a>",
"    ]. The acute chest syndrome, renal failure, seizures, a baseline white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL,",
"    </span>",
"    and a low level of fetal hemoglobin (HbF) were all associated with an increased risk of early death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Long-term survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little consistent information describing determinants of long-term survival in SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/150-154\">",
"     150-154",
"    </a>",
"    ]. A small study reported on 102 individuals with SCD-SS who survived beyond their 60th birthday (range: 60 to 85 years, 65 percent women); none had ever received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/154\">",
"     154",
"    </a>",
"    ]. Their HbF levels averaged 4.9 percent higher than values extrapolated from a Jamaican cohort study, exceeding 10 percent in 24 and 14 percent of the women and men, respectively. Coexisting alpha thalassemia did not appear to promote survival in this group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Causes of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centralized Pathology Unit for Sickle Cell Disease has collected a series of 306 autopsies of individuals with SCD, accrued between 1929 and 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/155\">",
"     155",
"    </a>",
"    ]. The mode of dying was sudden and unexpected in 40 percent, within 24 hours after presentation in another 28 percent, and followed acute events in 63 percent.",
"   </p>",
"   <p>",
"    Infection was the most common cause of death for all sickle cell disease variants and all ages. As an example, infection was directly or indirectly responsible for 85 percent of deaths in children with SCD-SS less than three years of age. The portal of entry for infection was predominantly the respiratory tract in children, while in adults the portal appeared to be dictated by the sites of underlying chronic organ injury.",
"   </p>",
"   <p>",
"    For the 244 autopsied cases with homozygous sickle cell anemia, the most common sickle cell-related causes of death were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection - 48 percent",
"     </li>",
"     <li>",
"      Stroke - 10 percent",
"     </li>",
"     <li>",
"      Complications of therapy - 7 percent",
"     </li>",
"     <li>",
"      Splenic sequestration - 7 percent",
"     </li>",
"     <li>",
"      Thromboembolism - 5 percent",
"     </li>",
"     <li>",
"      Renal failure - 4 percent",
"     </li>",
"     <li>",
"      Pulmonary hypertension - 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study that analyzed clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autopsy findings among 141 adults with SCD seen at a single institution from 1976 to 2001, pulmonary hypertension was the leading finding at the time of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Estimating disease severity and risk of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Bayesian network model has been proposed to estimate SCD severity as well as the risk of death within five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/156\">",
"     156",
"    </a>",
"    ]. Input into this model requires clinical as well as laboratory markers of disease severity, and has been validated using data from two other data sets. However, these data have not been validated from others outside of the original investigators.",
"   </p>",
"   <p>",
"    A \"disease severity score calculator\", based on this work, is available at",
"    <a class=\"external\" href=\"file://www.bu.edu/sicklecell/downloads/Projects\">",
"     www.bu.edu/sicklecell/downloads/Projects",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/157\">",
"     157",
"    </a>",
"    ]. However, this model has not been independently replicated. Therefore, making inferences about prognosis based upon the results of this model should be limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NHLBI has published a clinical guide for health care practitioners (The Management of Sickle Cell Disease, 2004), which is available on its website at",
"    <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/prof/blood/sickle/index.htm\">",
"     file://www.nhlbi.nih.gov/health/prof/blood/sickle/index.htm",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/157\">",
"     157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention has a website that provides additional information concerning sickle cell trait and sickle cell disease. It is available at",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncbddd/sicklecell/index.html\">",
"     www.cdc.gov/ncbddd/sicklecell/index.html",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/157\">",
"     157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A clinical overview of sickle cell disease, focusing on prevention, diagnosis, treatment, practice improvement, and patient information is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/0/39946/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=see_link\">",
"       \"Patient information: Sickle cell anemia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22723?source=see_link\">",
"       \"Patient information: When your child has sickle cell disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with sickle cell disease (SCD) should be seen regularly by the clinician and treatment team as part of a comprehensive health care maintenance program. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all individuals with SCD be vaccinated against common pathogens (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Common pathogens include Streptococcus pneumoniae, Haemophilus influenzae type B, Neisseria meningitidis, hepatitis B, seasonal influenza and H1N1 influenza. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Infection control and prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All individuals with SCD should begin antibiotic prophylaxis within the first three months of life. We suggest that all individuals with SCD receive antibiotic prophylaxis until age five, rather than a shorter duration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The decision of whether to continue antibiotic prophylaxis at age five must be made on a case-by-case basis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Infection control and prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all individuals with SCD receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also use a multivitamin",
"      <strong>",
"       without",
"      </strong>",
"      iron in all patients, and we replace vitamin D and calcium, which are often deficient, as needed. (See",
"      <a class=\"local\" href=\"#H30509050\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most individuals with symptomatic SCD should receive treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      . This important issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"       \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals with SCD are at risk for cerebrovascular accidents and proliferative retinopathy. For children with hemoglobin SS or SBeta(0) thalassemia or other sickle cell disease syndromes with low baseline hemoglobins, we recommend that transcranial Doppler ultrasound evaluation of cerebral blood flow for individuals under the age of 16 and funduscopic examination for all ages be performed periodically to screen individuals for these complications (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Routine evaluations and treatments'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H3#H3\">",
"       \"Cerebrovascular complications of sickle cell disease\", section on 'Cerebral infarction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additional routine evaluations are directed towards detecting and preventing end organ damage. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Routine evaluations and treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All individuals with SCD who present with acute pain due to a probable vasoocclusive crisis should receive adequate oral hydration, or intravenous hydration if they are hypovolemic, as well as pain control. We suggest an intravenous opiate as initial therapy, rather than a non-opiate analgesic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For individuals with a prior acute pain episode, we recommend an opioid selection and dose similar to that effectively employed during the prior episode(s). For other individuals,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      are reasonable alternatives. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pain management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=see_link\">",
"       \"Acute pain management in adults with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood transfusion. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Transfusion therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Indications for simple blood transfusion therapy include preparation for surgery in individuals with SCD-SS or acute symptomatic anemia resulting from reticulocytopenia.",
"     </li>",
"     <li>",
"      Indications for acute blood transfusion therapy (exchange transfusion or red blood cell pheresis techniques) include acute stroke, acute multi-organ failure, acute chest syndrome with evidence of clinical deterioration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory failure.",
"     </li>",
"     <li>",
"      Indications for prophylactic blood transfusion therapy include primary or secondary stroke prevention. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H3#H3\">",
"       \"Cerebrovascular complications of sickle cell disease\", section on 'Cerebral infarction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For individuals with SCD who have been selected for transfusion therapy, we recommend the use of blood that has been leukoreduced and matched at the ABO, D, C, E, and Kell loci whenever such blood is available (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The goal for exchange transfusion therapy is a hemoglobin S concentration &lt;30 percent, while the overall goal for simple transfusion therapy for symptomatic anemia is a hemoglobin not higher than 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Alloimmunization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematopoietic cell transplantation is the only available curative options in individuals with sickle cell disease. This important issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"       \"Hematopoietic cell transplantation in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/1\">",
"      Amrolia PJ, Almeida A, Halsey C, et al. Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options. Br J Haematol 2003; 120:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/2\">",
"      Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/3\">",
"      Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010; 376:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/4\">",
"      Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-Care Indicators for Children With Sickle Cell Disease. Pediatrics 2011; 128:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/5\">",
"      Woods KF, Johnson JA, Kutlar A, et al. Sickle cell disease telemedicine network for rural outreach. J Telemed Telecare 2000; 6:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/6\">",
"      Patik M, Phillips L, Kladny B, et al. Structured telephone-based outreach using nonmedical personnel can improve adherence to comprehensive care in families of children with sickle cell disease. Am J Hematol 2006; 81:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/7\">",
"      de Montalembert M, Ferster A, Colombatti R, et al. ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. Am J Hematol 2011; 86:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/8\">",
"      Steinberg MH. In the clinic. Sickle cell disease. Ann Intern Med 2011; 155:ITC31.",
"     </a>",
"    </li>",
"    <li>",
"     The management of sickle cell disease. National Institutes of Health; National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources. NIH publication 04-2117, revised 2004. This reference is also available for downloading or purchase at: www.nhlbi.nih.gov/health/prof/blood/sickle/ (Accessed on June 25, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/10\">",
"      Wong WY, Overturf GD, Powars DR. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. Clin Infect Dis 1992; 14:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/11\">",
"      Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998; 133:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/12\">",
"      Marcinak JF, Frank AL, Labotka RL, et al. Immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in 3- to 17-month-old infants with sickle cell diseases. J Pediatr 1991; 118:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/13\">",
"      Bjornson AB, Falletta JM, Verter JI, et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr 1996; 129:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/14\">",
"      Strouse JJ, Reller ME, Bundy DG, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood 2010; 116:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/15\">",
"      Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428.",
"     </a>",
"    </li>",
"    <li>",
"     (file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm (Accessed on January 07, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/17\">",
"      Wong WY, Powars DR, Chan L, et al. Polysaccharide encapsulated bacterial infection in sickle cell anemia: a thirty year epidemiologic experience. Am J Hematol 1992; 39:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/18\">",
"      Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995; 127:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/19\">",
"      Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/20\">",
"      John AB, Ramlal A, Jackson H, et al. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J (Clin Res Ed) 1984; 288:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/21\">",
"      Riddington C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev 2002; :CD003427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/22\">",
"      Buchanan GR, Smith SJ. Pneumococcal septicemia despite pneumococcal vaccine and prescription of penicillin prophylaxis in children with sickle cell anemia. Am J Dis Child 1986; 140:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/23\">",
"      Ellison AM, Ota KV, McGowan KL, Smith-Whitley K. Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population. Pediatr Infect Dis J 2012; 31:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/24\">",
"      Sox CM, Cooper WO, Koepsell TD, et al. Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease. JAMA 2003; 290:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/25\">",
"      Kawchak DA, Schall JI, Zemel BS, et al. Adequacy of dietary intake declines with age in children with sickle cell disease. J Am Diet Assoc 2007; 107:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/26\">",
"      Hyacinth HI, Gee BE, Hibbert JM. The Role of Nutrition in Sickle Cell Disease. Nutr Metab Insights 2010; 3:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/27\">",
"      Phillips G, Tangney CC. Relationship of plasma alpha tocopherol to index of clinical severity in individuals with sickle cell anemia. Am J Hematol 1992; 41:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/28\">",
"      Claster S, Wood JC, Noetzli L, et al. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol 2009; 84:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/29\">",
"      Arruda MM, Mecabo G, Rodrigues CA, et al. Antioxidant vitamins C and E supplementation increases markers of haemolysis in sickle cell anaemia patients: a randomized, double-blind, placebo-controlled trial. Br J Haematol 2013; 160:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/30\">",
"      PEARSON HA, COBB WT. FOLIC ACID STUDIES IN SICKLE-CELL ANEMIA. J Lab Clin Med 1964; 64:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/31\">",
"      Rabb LM, Grandison Y, Mason K, et al. A trial of folate supplementation in children with homozygous sickle cell disease. Br J Haematol 1983; 54:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/32\">",
"      van der Dijs FP, Schnog JJ, Brouwer DA, et al. Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. Am J Hematol 1998; 59:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/33\">",
"      Kennedy TS, Fung EB, Kawchak DA, et al. Red blood cell folate and serum vitamin B12 status in children with sickle cell disease. J Pediatr Hematol Oncol 2001; 23:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/34\">",
"      Lal A, Fung EB, Pakbaz Z, et al. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer 2006; 47:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/35\">",
"      Osunkwo I, Hodgman EI, Cherry K, et al. Vitamin D deficiency and chronic pain in sickle cell disease. Br J Haematol 2011; 153:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/36\">",
"      Osunkwo I, Ziegler TR, Alvarez J, et al. High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study. Br J Haematol 2012; 159:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/37\">",
"      Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med 1997; 102:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/38\">",
"      DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012; 119:3684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/39\">",
"      Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/40\">",
"      Valadi N, Silva GS, Bowman LS, et al. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology 2006; 67:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/41\">",
"      Sampaio Silva G, Vicari P, Figueiredo MS, et al. Transcranial Doppler in adult patients with sickle cell disease. Cerebrovasc Dis 2006; 21:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/42\">",
"      Cohen RT, Madadi A, Blinder MA, et al. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. Am J Hematol 2011; 86:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/43\">",
"      Aguilar CM, Neumayr LD, Eggleston BE, et al. Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children's Hospital Oakland Hip Evaluation Scale--a modification of the Harris Hip Score. Arch Phys Med Rehabil 2005; 86:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/44\">",
"      Pappo A, Buchanan GR. Acute splenic sequestration in a 2-month-old infant with sickle cell anemia. Pediatrics 1989; 84:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/45\">",
"      Solanki DL, Kletter GG, Castro O. Acute splenic sequestration crises in adults with sickle cell disease. Am J Med 1986; 80:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/46\">",
"      Orringer EP, Fowler VG Jr, Owens CM, et al. Case report: splenic infarction and acute splenic sequestration in adults with hemoglobin SC disease. Am J Med Sci 1991; 302:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/47\">",
"      Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/48\">",
"      Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 2003; 120:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/49\">",
"      Ballas SK. Treatment of pain in adults with sickle cell disease. Am J Hematol 1990; 34:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/50\">",
"      Elander J, Lusher J, Bevan D, et al. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage 2004; 27:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/51\">",
"      Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood 2008; 111:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/52\">",
"      Darbari DS, Minniti CP, Rana S, van den Anker J. Pharmacogenetics of morphine: Potential implications in sickle cell disease. Am J Hematol 2008; 83:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/53\">",
"      Sutton M, Atweh GF, Cashman TD, Davis WT. Resolving conflicts: misconceptions and myths in the care of the patient with sickle cell disease. Mt Sinai J Med 1999; 66:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/54\">",
"      Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health 2003; 93:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/55\">",
"      Geller AK, O'Connor MK. The sickle cell crisis: a dilemma in pain relief. Mayo Clin Proc 2008; 83:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/56\">",
"      Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008; 299:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/57\">",
"      Zempsky WT. Treatment of sickle cell pain: fostering trust and justice. JAMA 2009; 302:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/58\">",
"      Ware MA, Hambleton I, Ochaya I, Serjeant GR. Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? Br J Haematol 1999; 104:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/59\">",
"      Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000; 95:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/60\">",
"      Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol 2004; 126:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/61\">",
"      Frei-Jones MJ, Baxter AL, Rogers ZR, Buchanan GR. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. J Pediatr 2008; 152:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/62\">",
"      Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008; 148:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/63\">",
"      Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med 1992; 116:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/64\">",
"      Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manag 2005; 10:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/65\">",
"      Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/66\">",
"      Moulin D. Use of methadone for neuropathic pain. Pain Res Manag 2003; 8:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/67\">",
"      Powars D, Overturf G, Weiss J, et al. Pneumococcal septicemia in children with sickle cell anemia. Changing trend of survival. JAMA 1981; 245:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/68\">",
"      Kravis E, Fleisher G, Ludwig S. Fever in children with sickle cell hemoglobinopathies. Am J Dis Child 1982; 136:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/69\">",
"      Rahimy MC, Gangbo A, Ahouignan G, et al. Outpatient management of fever in children with sickle cell disease (SCD) in an African setting. Am J Hematol 1999; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/70\">",
"      Williams LL, Wilimas JA, Harris SC, et al. Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease. J Pediatr Hematol Oncol 1996; 18:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/71\">",
"      Rogers ZR, Morrison RA, Vedro DA, Buchanan GR. Outpatient management of febrile illness in infants and young children with sickle cell anemia. J Pediatr 1990; 117:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/72\">",
"      Wilimas JA, Flynn PM, Harris S, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med 1993; 329:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/73\">",
"      Viner Y, Hashkes PJ, Yakubova R, et al. Severe hemolysis induced by ceftriaxone in a child with sickle-cell anemia. Pediatr Infect Dis J 2000; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/74\">",
"      Bernini JC, Mustafa MM, Sutor LJ, Buchanan GR. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J Pediatr 1995; 126:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/75\">",
"      Quillen K, Lane C, Hu E, et al. Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis J 2008; 27:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/76\">",
"      Robinson MG, Watson RJ. Pneumococcal meningitis in sickle-cell anemia. N Engl J Med 1966; 274:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/77\">",
"      Poncz M, Kane E, Gill FM. Acute chest syndrome in sickle cell disease: etiology and clinical correlates. J Pediatr 1985; 107:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/78\">",
"      Syrogiannopoulos GA, McCracken GH Jr, Nelson JD. Osteoarticular infections in children with sickle cell disease. Pediatrics 1986; 78:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/79\">",
"      Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood 1993; 81:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/80\">",
"      Davies SC, Roberts-Harewood M. Blood transfusion in sickle cell disease. Blood Rev 1997; 11:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/81\">",
"      Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 2007; 21:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/82\">",
"      Quirolo K. How do I transfuse patients with sickle cell disease? Transfusion 2010; 50:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/83\">",
"      Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/84\">",
"      Wang WC, Morales KH, Scher CD, et al. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. J Pediatr 2005; 147:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/85\">",
"      Kalff A, Dowsing C, Grigg A. The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults. Br J Haematol 2010; 149:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/86\">",
"      Driss F, Moh-Klaren J, Tertian G. Regular automated erythrocytapheresis in sickle cell patients. Br J Haematol 2011; 154:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/87\">",
"      Charache S. Treatment of sickle cell anemia. Annu Rev Med 1981; 32:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/88\">",
"      Carrara P, Balocco M, Pinto V, et al. Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: a long-term follow-up. Am J Hematol 2010; 85:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/89\">",
"      Nieburg PI, Stockman JA. Rapid correction of anemia with partial exchange transfusion. Am J Dis Child 1977; 131:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/90\">",
"      Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J Pediatr 2006; 149:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/91\">",
"      Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med 1994; 96:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/92\">",
"      Thame JR, Hambleton IR, Serjeant GR. RBC transfusion in sickle cell anemia (HbSS): experience from the Jamaican Cohort Study. Transfusion 2001; 41:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/93\">",
"      Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/94\">",
"      Vichinsky EP, Neumayr LD, Haberkern C, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. Am J Hematol 1999; 62:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/95\">",
"      Waldron P, Pegelow C, Neumayr L, et al. Tonsillectomy, adenoidectomy, and myringotomy in sickle cell disease: perioperative morbidity. Preoperative Transfusion in Sickle Cell Disease Study Group. J Pediatr Hematol Oncol 1999; 21:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/96\">",
"      Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Blood 1997; 89:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/97\">",
"      Koshy M, Weiner SJ, Miller ST, et al. Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Blood 1995; 86:3676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/98\">",
"      Neumayr L, Koshy M, Haberkern C, et al. Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group. Am J Hematol 1998; 57:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/99\">",
"      Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/100\">",
"      Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/101\">",
"      Olujohungbe A, Hambleton I, Stephens L, et al. Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol 2001; 113:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/102\">",
"      Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/103\">",
"      Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987; 27:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/104\">",
"      Tahhan HR, Holbrook CT, Braddy LR, et al. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994; 34:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/105\">",
"      Castilho L, Rios M, Bianco C, et al. DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients. Transfusion 2002; 42:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/106\">",
"      Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002; 42:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/107\">",
"      Afenyi-Annan A, Willis MS, Konrad TR, Lottenberg R. Blood bank management of sickle cell patients at comprehensive sickle cell centers. Transfusion 2007; 47:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/108\">",
"      Ameen R, Al Shemmari S, Al-Bashir A. Red blood cell alloimmunization among sickle cell Kuwaiti Arab patients who received red blood cell transfusion. Transfusion 2009; 49:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/109\">",
"      Vichinsky EP. The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells. Immunohematology 2012; 28:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/110\">",
"      Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/111\">",
"      Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/112\">",
"      Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/113\">",
"      Price CL, Boyd JH, Watkins AR, et al. Mailing of a sickle cell disease educational packet increases blood donors within an African American community. Transfusion 2006; 46:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/114\">",
"      Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005; 129:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/115\">",
"      Ribeiro KR, Guarnieri MH, da Costa DC, et al. DNA array analysis for red blood cell antigens facilitates the transfusion support with antigen-matched blood in patients with sickle cell disease. Vox Sang 2009; 97:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/116\">",
"      Mali S, Kachur SP, Arguin PM, et al. Malaria surveillance--United States, 2010. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/117\">",
"      Herwaldt BL, Linden JV, Bosserman E, et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/118\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/119\">",
"      Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/120\">",
"      Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/121\">",
"      Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001; 38:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/122\">",
"      Perronne V, Roberts-Harewood M, Bachir D, et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J 2002; 3:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/123\">",
"      Ancel D, Amiot X, Chaslin-Ferbus D, et al. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol 2009; 21:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/124\">",
"      Hurtova M, Bachir D, Lee K, et al. Transplantation for liver failure in patients with sickle cell disease: challenging but feasible. Liver Transpl 2011; 17:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/125\">",
"      Lang T, Berquist WE, So SK, et al. Liver transplantation in a child with sickle cell anemia. Transplantation 1995; 59:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/126\">",
"      Porter JB, Shah FT. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am 2010; 24:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/127\">",
"      Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/128\">",
"      Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011; 364:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/129\">",
"      Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/130\">",
"      Singer ST, Quirolo K, Nishi K, et al. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher 1999; 14:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/131\">",
"      Cohen A, Schwartz E. Excretion of iron in response to deferoxamine in sickle cell anemia. J Pediatr 1978; 92:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/132\">",
"      Vichinsky E. Iron overload and iron chelation therapy in pediatric patients. US Hematology 2009; 2:64. Online access: file://www.touchbriefings.com/pdf/3324/elliott_vichinsky.pdf",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/133\">",
"      Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/134\">",
"      Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/135\">",
"      Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011; 154:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/136\">",
"      Lal A, Sweeters N, Ng V, et al. Combined chelation therapy with deferasirox and deferoxamine in transfusion-dependent thalassemia. Blood (ASH Annual Meeting Abstracts) 2010; 116:4269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/137\">",
"      Lucania G, Vitrano A, Filosa A, Maggio A. Chelation treatment in sickle-cell-anaemia: much ado about nothing? Br J Haematol 2011; 154:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/138\">",
"      Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet 1998; 351:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/139\">",
"      Adler BK, Salzman DE, Carabasi MH, et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001; 97:3313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/140\">",
"      Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 2001; 97:3998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/141\">",
"      Abboud MR, Taylor EC, Habib D, et al. Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease. Br J Haematol 2000; 111:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/142\">",
"      Fitzhugh CD, Hsieh MM, Bolan CD, et al. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy 2009; 11:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/143\">",
"      Blau CA. Adverse effects of G-CSF in sickle cell syndromes. Blood 2001; 97:3682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/144\">",
"      Kang EM, Areman EM, David-Ocampo V, et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002; 99:850.",
"     </a>",
"    </li>",
"    <li>",
"     Diggs LM. Anatomic lesions in sickle cell disease. In: Sickle Cell Disease Diagnosis, Management, Education, and Research, Abramson H, Bertles JF, Wethers DL (Eds), Mosby, St. Louis 1973. p.189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/146\">",
"      Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001; 357:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/147\">",
"      Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004; 103:4023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/148\">",
"      Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/149\">",
"      Quinn CT, Lee NJ, Shull EP, et al. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood 2008; 111:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/150\">",
"      Morris J, Dunn D, Beckford M, et al. The haematology of homozygous sickle cell disease after the age of 40 years. Br J Haematol 1991; 77:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/151\">",
"      McKerrell TD, Cohen HW, Billett HH. The older sickle cell patient. Am J Hematol 2004; 76:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/152\">",
"      Steinberg MH, Ballas SK, Brunson CY, Bookchin R. Sickle cell anemia in septuagenarians. Blood 1995; 86:3997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/153\">",
"      Losada R, Bravo I, Capildeo K, Charles K. Is the group of older sickle cell disease patients from Trinidad and Tobago different? Am J Hematol 2006; 81:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/154\">",
"      Serjeant GR, Higgs DR, Hambleton IR. Elderly survivors with homozygous sickle cell disease. N Engl J Med 2007; 356:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/155\">",
"      Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003; 123:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/0/39946/abstract/156\">",
"      Sebastiani P, Nolan VG, Baldwin CT, et al. A network model to predict the risk of death in sickle cell disease. Blood 2007; 110:2727.",
"     </a>",
"    </li>",
"    <li>",
"     www.aamds.org/aplastic (Accessed on July 12, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7114 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39946=[""].join("\n");
var outline_f39_0_39946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Infection control and prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prophylactic penicillin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30509050\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Routine evaluations and treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SPLENIC SEQUESTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H458917\">",
"      Acute pain episode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Febrile episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Specific infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TRANSFUSION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Transfusion techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Transfusion volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prophylactic preoperative transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Hemoglobin SC disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1158337\">",
"      - Transmission of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Excessive iron stores",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1158060\">",
"      - Complications and evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1158200\">",
"      - Chelation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      GRANULOCYTE COLONY-STIMULATING FACTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prediction of adverse outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Long-term survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Causes of death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Estimating disease severity and risk of death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7114\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7114|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/59/31676\" title=\"table 1\">",
"      Infection risk of blood products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9066?source=related_link\">",
"      Acute chest syndrome in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17114?source=related_link\">",
"      Acute pain management in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=related_link\">",
"      Bone and joint complications in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=related_link\">",
"      Diagnosis and management of priapism in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2842?source=related_link\">",
"      Hepatic manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/1/39961?source=related_link\">",
"      Management of fever in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=related_link\">",
"      Patient information: Sickle cell anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22723?source=related_link\">",
"      Patient information: When your child has sickle cell disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=related_link\">",
"      Pregnancy in women with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=related_link\">",
"      Prenatal testing for the hemoglobinopathies and thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/1/38937?source=related_link\">",
"      Routine comprehensive care for children with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27480?source=related_link\">",
"      The incompatible crossmatch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_0_39947="Properties of hydroxyurea";
var content_f39_0_39947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical properties of hydroxyurea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Characteristic",
"      </td>",
"      <td class=\"subtitle1\">",
"       Hydroxyurea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Drug class",
"      </td>",
"      <td>",
"       Antimetabolite",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mechanism of action",
"      </td>",
"      <td>",
"       Not genotoxic, impairs DNA repair by inhibiting ribonucleotide reductase",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Specificity",
"      </td>",
"      <td>",
"       Affects all cell lines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pharmacology",
"      </td>",
"      <td>",
"       Half-life four hours, renal excretion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Starting dose",
"      </td>",
"      <td>",
"       15 mg/kg per day PO",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Onset of action",
"      </td>",
"      <td>",
"       Three to five days when the usual starting dose is employed (15 mg/kg per day).*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Side effects observed in &gt;10 percent of patients",
"      </td>",
"      <td>",
"       Neutropenia, anemia, oral ulcers, hyperpigmentation, rash, nail changes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Side effects observed in &le;10 percent of patients",
"      </td>",
"      <td>",
"       Ankle ulcers, lichen planus-like lesions of the mouth and skin, nausea, diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rare side effects",
"      </td>",
"      <td>",
"       Fever, liver function test abnormalties",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contraindications",
"      </td>",
"      <td>",
"       Neutropenia, pregnancy, chilbearing potential, breast feeding",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Annual cost",
"      </td>",
"      <td>",
"       $1700.00, for 500 mg three times daily dose",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The onset of action is 24 to 48 hours when a higher dose of hydroxyurea is used for hyperleukocytosis (ie, 50-100 mg/kg per day).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39947=[""].join("\n");
var outline_f39_0_39947=null;
var title_f39_0_39948="Treatment of leprosy in adults";
var content_f39_0_39948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Multidrug regimens for treatment of leprosy in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        National Hansens Disease Program (NHDP)*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        World Health Organization (WHO)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle2\">",
"        Duration",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle2\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Tuberculoid (\"paucibacillary\"): TT and BT",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dapsone",
"       </td>",
"       <td>",
"        100 mg daily",
"       </td>",
"       <td rowspan=\"2\">",
"        12 months",
"       </td>",
"       <td>",
"        100 mg daily",
"       </td>",
"       <td rowspan=\"2\">",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rifampin",
"       </td>",
"       <td>",
"        600 mg daily",
"       </td>",
"       <td>",
"        600 mg once a month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Lepromatous (\"multibacillary\"): LL, BL, BB",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dapsone",
"       </td>",
"       <td>",
"        100 mg daily",
"       </td>",
"       <td rowspan=\"3\">",
"        24 months",
"       </td>",
"       <td>",
"        100 mg daily",
"       </td>",
"       <td rowspan=\"3\">",
"        12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rifampin",
"       </td>",
"       <td>",
"        600 mg daily",
"       </td>",
"       <td>",
"        600 mg once a month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clofazimine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        50 mg daily",
"       </td>",
"       <td>",
"        300 mg once a month, and 50 mg daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Additional information available at the NHDP website:",
"     <a href=\"file://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html\" target=\"_blank\">",
"      file://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html",
"     </a>",
"     .",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Additional information available at the WHO website:",
"      <a href=\"file://www.searo.who.int/en/Section10/Section20/Section2000.htm\" target=\"_blank\">",
"       file://www.searo.who.int/en/Section10/Section20/Section2000.htm",
"      </a>",
"      .",
"      <br>",
"       &Delta; The durations of treatment outlined by NHDP are sufficient even though large numbers of dead bacilli may remain in tissues for several years before they are eliminated by physiologic processes. There is no evidence that prolonged treatment hastens the elimination of these dead organisms.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        TT, BT, BB, BL, and LL refer to the Ridley-Jopling classification (see text).",
"        <br>",
"         &sect; In the United States, the NHDP holds the Investigational New Drug (IND) application for clofazimine treatment of leprosy. For further information or to request investigator status to use clofazimine, contact the NHDP: 1-800-642-2477. Clofazimine should be taken either with or immediately after food or milk to facilitate absorption. If clofazimine is not tolerated, daily minocycline may be substituted.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39948=[""].join("\n");
var outline_f39_0_39948=null;
var title_f39_0_39949="Different forms of CAH";
var content_f39_0_39949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of different forms of congenital adrenal hyperplasia*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        21-hydroxylase deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        11-beta-hydroxylase deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aldosterone synthase deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        17-alpha-hydroxylase deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        3-beta-hydroxysteroid dehydrogenase deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lipoid hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defective gene",
"       </td>",
"       <td>",
"        CYP21A2 (P450c21)",
"       </td>",
"       <td>",
"        CYP11B1 (P450c11)",
"       </td>",
"       <td>",
"        CYP11B2 (P450aldo)",
"       </td>",
"       <td>",
"        CYP17 (P450c17)",
"       </td>",
"       <td>",
"        HSD3B2 (3-Beta-HSD)",
"       </td>",
"       <td>",
"        StAR (Steroid acute regulatory protein)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Ambiguous genitalia",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        + in females",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        + in females",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        No",
"       </td>",
"       <td>",
"        + in males",
"       </td>",
"       <td>",
"        + in males",
"       </td>",
"       <td>",
"        + in males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No puberty in females",
"       </td>",
"       <td>",
"        Mild in females",
"       </td>",
"       <td>",
"        No puberty in females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Addisonian crisis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Salt wasting only",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incidence (general population)",
"       </td>",
"       <td>",
"        1:11000 - 23000",
"       </td>",
"       <td>",
"        1:100000",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"7\" rowspan=\"1\">",
"        Hormones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glucocorticoids",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Corticosterone normal",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mineralocorticoids",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\" rowspan=\"2\">",
"        Androgens",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        Normal",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"1\" rowspan=\"2\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr; in males",
"       </td>",
"       <td rowspan=\"2\">",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        &uarr; in females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Estrogens",
"       </td>",
"       <td class=\"sublist_other\">",
"        Relatively &darr; in females",
"       </td>",
"       <td class=\"sublist_other\">",
"        Relatively &darr; in females",
"       </td>",
"       <td class=\"sublist_other\">",
"        Normal",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"7\" rowspan=\"1\">",
"        Physiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blood pressure",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Na balance",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        K balance",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acidosis",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        &plusmn; Alkalosis",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td class=\"sublist_other\">",
"        &plusmn; Alkalosis",
"       </td>",
"       <td class=\"sublist_other\">",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated steroid metabolites",
"       </td>",
"       <td>",
"        17-OHP",
"       </td>",
"       <td>",
"        DOC, 11- deoxycortisol",
"       </td>",
"       <td>",
"        Corticosterone, &plusmn; 18-hydroxy- corticosterone",
"       </td>",
"       <td>",
"        DOC corticosterone",
"       </td>",
"       <td>",
"        DHEA, 17&Delta;5Preg",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     17-OHP: 17-hydroxyprogesterone; DOC: deoxycorticosterone; DHEA: dehydroepiandrosterone; 17&Delta;5Preg: 17-delta-5-hydroxypregnenolone.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: White PC, Speiser PW. Endocr Rev 2000; 21:245. Copyright 2000 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39949=[""].join("\n");
var outline_f39_0_39949=null;
var title_f39_0_39950="Initial approach to patients with newly diagnosed NSCLC";
var content_f39_0_39950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Initial approach to patients with newly diagnosed non-small cell lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; TKI: tyrosine kinase inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39950=[""].join("\n");
var outline_f39_0_39950=null;
var title_f39_0_39951="Positive sharp wave to fibrillation";
var content_f39_0_39951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Transition of a positive sharp wave to a fibrillation potential",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 236px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In (A) and (B) the sweep is free running. The traces in (B) represent a continuation of the EMG signal after the last trace in (A). In (C), the waveforms from (A) and (B) are superimposed using amplitude trigger and delay line. Calibration is 200 microV/division and 10 ms/division in (A) and (B), and 100 microV/division and 1 ms/division in (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nandedkar, SD, Barkhaus, PE, Sanders, DB, Stalberg, EV. Some observations on fibrillations and positive sharp waves. Muscle Nerve 2004; 23:888. Copyright &copy;2004 John Wiley &amp; Sonsm Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_0_39951=[""].join("\n");
var outline_f39_0_39951=null;
